Variant Annotation ID,Variant/Haplotypes,Gene,Drug(s),PMID,Phenotype Category,Significance,Notes,Sentence,Alleles,Specialty Population
1451159680,rs5031016,CYP2A6,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose. Described as CYP2A6*7 in this study.,Allele G is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele A.,G,
1451306860,CYP2C9*11,CYP2C9,warfarin,33350885,Dosage,not stated,This case suggests that CYP2C9 *11/*11 carriers require approximately two thirds less warfarin than CYP2C9 normal function homozygotes.,CYP2C9 *11/*11 is associated with decreased dose of warfarin.,*11/*11,
1451865260,rs9923231,VKORC1,warfarin,35880564,Dosage,not stated,"as part of dosing algorithm specifically for Honghe Prefecture compared to Han Chinese. "" The present study found that there was only one case with CYP2C9*1/*2 heterozygous mutation (0.005%) and two patients with VKORC1 GG wild-type homozygous genotype (G>A mutation rate 98%) in Han Chinese. Our studies did not observe these rare genotypes in Honghe minorities.""",Genotype TT is associated with decreased dose of warfarin in people with mechanical heart valve replacement.,TT,
1451339940,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, CYP2C9*2 allele is associated with 6.8mg/week less warfarin dose requirement compared to wild-type homozygotes.",CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2,
1451340000,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, CYP2C9*3 allele is associated with 12.5mg/week less warfarin dose requirement compared to wild-type homozygotes.",CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3,
1451340007,"CYP2C9*1, CYP2C9*5",CYP2C9,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, CYP2C9*5 allele is associated with 13.4mg/week less warfarin dose requirement compared to wild-type homozygotes.",CYP2C9 *1/*5 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*5,
1451340040,"CYP2C9*1, CYP2C9*11",CYP2C9,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, CYP2C9*11 allele is associated with 5.4mg/week less warfarin dose requirement compared to wild-type homozygotes.",CYP2C9 *1/*11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*11,
1451340046,rs9923231,VKORC1,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, this variant is associated with 18.1mg/week less warfarin dose requirement compared to wild-type homozygotes.",Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1451340140,rs2884737,VKORC1,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, this variant is associated with 19.6mg/week less warfarin dose requirement compared to wild-type homozygotes.",Genotypes AC + CC are associated with decreased dose of warfarin as compared to genotype AA.,AC + CC,
1448257090,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,27488389,Dosage,yes,in Han Chinese.,CYP2C9 *3/*3 + *1/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3/*3 + *1/*3,
1448257121,rs41301394,POR,warfarin,27488389,Dosage,yes,in Han Chinese. The SNP POR*37 831-35C>T was shown to be a minor but statistically significant factor associated with inter-individual variation in warfarin maintenance dose in Han Chinese. The contribution of POR*37 831-35C>T to warfarin dose variation was only 3.9 %.,Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
1448257131,rs10239977,POR,warfarin,27488389,Dosage,no,in Han Chinese. This variant is also called POR 366+89C>T.,Genotypes CT + TT is not associated with dose of warfarin as compared to genotype CC.,CT + TT,
1451214044,"UGT1A1*1, UGT1A1*28",UGT1A1,warfarin,25312789,Dosage,yes,Classification II divided the individuals into two dose ranges: <70 mg and >=70 mg warfarin/week,UGT1A1 *1/*28 + *28/*28 is associated with increased dose of warfarin in people with Thromboembolism as compared to UGT1A1 *1/*1.,*1/*28 + *28/*28,
1451221900,rs9923231,VKORC1,warfarin,32559398,Dosage,yes,,Genotype AA is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotypes AG + GG.,AA,
1451221840,rs2260863,EPHX1,warfarin,32559398,Dosage,yes,"Authors describe effect for ""nonvariant CC homozygotes"", there were no GG homozygotes.",Genotype CC is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotype CG.,CC,
1451221905,rs1057910,CYP2C9,warfarin,32559398,Dosage,yes,There were no CC homozygotes. This variant is also known as *3. Also there were no rs1799853 carriers (*2).,Genotype AC is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA.,AC,
1184654383,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,24330000,"Dosage,""Efficacy""",yes,"A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - n=2 children had the *2/*2 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and *3 as rs1057910.",CYP2C9 *2/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.,*2/*2,Pediatric
1183701514,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,20421126,Dosage,yes,The study purpose was to develop a model for stable maintenance warfarin dose prediction. Most patients had a history of venous thromboembolism.,CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.,*1/*3,
827919897,"CYP2C9*1, CYP2C9*3",CYP2C9,"simvastatin,""warfarin""",22594507,"Dosage,""Metabolism/PK""",yes,"This influence on the magnitude of the simvastatin-warfarin drug-drug interaction was seen only in patients with the CYP2C9*3 allele. Multiple regression model predicted that simvastatin exposure would have no effect in noncarriers, but reduces warfarin dose by 25% in heterozygous *3 carriers and by 43% in homozygous *3 carriers. (Genotyping details not provided). [stat_test: multiple regression analysis]",CYP2C9 *3 is associated with decreased dose of warfarin when treated with simvastatin and warfarin.,*3,
827919905,"CYP2C9*1, CYP2C9*2",CYP2C9,"simvastatin,""warfarin""",22594507,"Dosage,""Metabolism/PK""",no,"Though *2 is associated with decreased dose of warfarin, it does not influence the magnitude of the simvastatin-warfarin drug-drug interaction on warfarin dose, which was seen only in patients with the CYP2C9*3 allele. (Genotyping details not provided). [stat_test: multiple regression analysis]",CYP2C9 *2 is not associated with decreased dose of warfarin when treated with simvastatin and warfarin.,*2,
827919924,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,22594507,"Dosage,""Metabolism/PK""",yes,[stat_test: multiple regression analysis],CYP2C9 *3 is associated with decreased dose of warfarin.,*3,
1448267984,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,21981797,Dosage,yes,"Patients with the *1/*3 diplotype had a lower mean warfarin dose (2.7+/-0.9 mg/day) than those with the *1/*1 genotype (4.9+/-2.5 mg/day). Additionally, this study developed a pharmacogenetic algorithm for warfarin dosing in Korean patients and then compared it against other pharmacogenetic algorithms; this variant was present in the algorithm.",CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation.,*1/*3,
1184510026,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,22549502,Dosage,yes,in Korean patients with mechanical cardiac valves.,CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*3,
827919910,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,22594507,"Dosage,""Metabolism/PK""",yes,[stat_test: multiple regression analysis],CYP2C9 *2 is associated with decreased dose of warfarin.,*2,
978614428,CYP2C9*2,CYP2C9,warfarin,22676192,"Dosage,""Metabolism/PK""",not stated,"in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664).",CYP2C9 *2 is associated with dose of warfarin.,*2,
1184756158,rs1057910,CYP2C9,warfarin,25126975,Dosage,yes,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model."" rs1057910 remained significantly associated with warfarin maintenance dose in the multivariate analysis.",Allele A is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.,A,
827864554,rs28371686,CYP2C9,warfarin,21228733,Dosage,yes,"This SNP defines CYP2C9*5. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1.",Allele G is associated with decreased dose of warfarin as compared to allele C.,G,
827864542,rs9923231,VKORC1,"phenprocoumon,""warfarin""",20833980,Dosage,yes,"in pediatric patients. In contrast to adult patients, age explained 28.3% of VKA dose variations; VKORC1 explained only 3.7%.",Genotype TT is associated with decreased dose of phenprocoumon or warfarin as compared to genotype CC.,TT,Pediatric
1183689393,rs9923231,VKORC1,warfarin,22990331,Dosage,yes,Patients with the TT genotype at this SNP needed significantly lower doses of warfarin and also showed significantly greater variability in dose as compared to patients with the CT or CC genotypes. Alleles have been complemented to the plus strand.,Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.,TT,
981754840,rs9923231,VKORC1,warfarin,23061746,Dosage,yes,"Comparison between GG, GA and AA was significant as was GG compared to GA and GG to AA. Please note that alleles have been complemented to the positive strand, based on comparison of allele frequencies in the paper and those available on dbSNP.",Allele T is associated with decreased dose of warfarin.,T,
1448276515,CYP4F2*3,CYP4F2,warfarin,26710337,Dosage,not stated,"This study assessed whether a pharmacogenetic algorithm, which included this variant as well as the VKORC1 rs9923231, CYP2C9*2 and CYP2C9*3 variants, is superior in overall anticoagulation control when compared to clinical standard of care.",CYP4F2 *3 is associated with dose of warfarin.,*3,
1446765933,rs2108622,CYP4F2,warfarin,26257249,Dosage,yes,"Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. Please note, alleles have been complimented to the + strand.",Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.,TT,
1448275984,rs2108622,CYP4F2,warfarin,21326313,Dosage,yes,"Patients with the CC genotype had a significantly lower dose of warfarin (3.0+/-1.5 mg/day) as compared to those with the TT genotype (3.5+/-2.5 mg/day). Additionally, this variant was included in an algorithm for determining warfarin dose.",Genotype CC is associated with decreased dose of warfarin as compared to genotype TT.,CC,
1450370810,rs2108622,CYP4F2,warfarin,30821933,Dosage,no,in Alaska Native and American Indian People.,Allele T is not associated with dose of warfarin as compared to allele C.,T,
1183701311,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,17989110,Dosage,not stated,Weekly maintenance doses were *1/*1: 38.6 mg; *1/*2: 28.5 mg.,CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2,
1183701305,rs9923231,VKORC1,warfarin,19679631,"Dosage,""Efficacy""",yes,"CC individuals required a daily maintenance dose of S-warfarin of 5.2 mg/day; TC individuals required 4.1 mg/day, and TT individuals required 2.4 mg/day.",Allele C is associated with increased dose of warfarin as compared to allele T.,C,
1183701419,"CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11",CYP2C9,warfarin,19802360,Dosage,yes,"Where (*2+*3+*5+*6+*11) are considered variant (*V), Average Daily maintenance dose for *1/*1 > *1/*V > *V/*V. *5,*6,*11 were only seen in African-Americans. This result was significant in European-Americans but not in African-Americans.",CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*11 + *2 + *3 + *5 + *6,
1451909688,"CYP2C9*1, CYP2C9*2, CYP2C9*11",CYP2C9,warfarin,35426132,Metabolism/PK,yes,Effect was for S-warfarin but not R-warfarin. It was also significant for increased halflife of S-warfarin but not R-warfarin.,CYP2C9 *1/*11 + *2/*11 is associated with decreased clearance of warfarin in healthy individuals as compared to CYP2C9 *1/*1.,*1/*11 + *2/*11,
1183701528,rs2108622,CYP4F2,warfarin,20421126,Dosage,yes,"The study purpose was to develop a model for stable maintenance warfarin dose prediction. Most patients had a history of venous thromboembolism. CC patients required a slightly lower dose than CT patients, who required a lower dose than TT patients.",Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele T.,C,
1183701501,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,20421126,Dosage,yes,"The study purpose was to develop a model for stable maintenance warfarin dose prediction. Most patients had a history of venous thromboembolism. *2 homozygous patients required a lower dose than *2 heterozygous patients, who required a lower dose than *1/*1 patients.",CYP2C9 *2 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1.,*2,
1450814028,"CYP2C9*1, CYP2C9*2, CYP2C9*24",CYP2C9,warfarin,16543980,Dosage,not stated,Case report of a patient with the *2/*24 genotype. The patient has reduced clearance of S-warfarin than matched patients with the *1/*2 genotype.,CYP2C9 *2/*24 is associated with decreased clearance of warfarin in women with Cardiomyopathies as compared to CYP2C9 *1/*2.,*2/*24,
1449192000,rs2108622,CYP4F2,warfarin,29201113,Dosage,yes,"Patients were divided into two groups: those who required more than 5 mg/day of warfarin (Group B) and those who required less than 5 mg/day of warfarin (Group A). Within Group B, the frequency of the T allele was 44% vs. 30% in Group A.",Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.,T,
769277894,rs9934438,VKORC1,warfarin,15358623,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1183701565,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,16160068,Dosage,no,This was a pilot study to compare traditional and PGx-guided dosing.,CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*3,
1183701573,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,15094935,Dosage,no,This was one case report. The patient was also reported to demonstrate impaired clearance of S-warfarin.,CYP2C9 *1/*3 is associated with decreased dose of warfarin.,*1/*3,
769277912,rs7294,"PRSS53,""VKORC1""",warfarin,17049586,Dosage,yes,,Genotype CT is associated with increased dose of warfarin as compared to genotype CC.,CT,
1447520262,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,19794411,Dosage,yes,,CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3,
1450814021,"CYP2C9*1, CYP2C9*2, CYP2C9*24",CYP2C9,warfarin,16543980,Dosage,not stated,Case report of a patient with the *2/*24 genotype. The patient has lower warfarin dose requirements (1.5mg/day) than matched patients with the *1/*2 genotype.,CYP2C9 *2/*24 is associated with decreased dose of warfarin in women with Cardiomyopathies as compared to CYP2C9 *1/*2.,*2/*24,
1451913560,rs4986893,CYP2C19,warfarin,36222113,Dosage,yes,"in meta-analysis of 4 studies. ""The warfarin maintenance doses in individuals with the A allele were significantly reduced (p < 0.001) by 10% (95% CI: 4–16%) compared with the carriers of the homozygous GG genotype""",Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1451913567,rs3814637,CYP2C19,warfarin,36222113,Dosage,yes,"in meta-analysis of 2 studies. ""Compared with the warfarin maintenance dose in carriers of the homozygous CC genotype, the warfarin maintenance dose in individuals with the TT genotype, CT genotype and T allele was significantly reduced by 34% (95% CI: 13–54%), 16% (95% CI: 8–24%) and 18% (95% CI: 10–26%), respectively.""",Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
982044373,rs17708472,VKORC1,warfarin,16611750,Dosage,no,,Allele A is not associated with increased dose of warfarin as compared to allele G.,A,
1451913583,rs4244285,CYP2C19,warfarin,36222113,Dosage,no,"in meta-analysis of 8 studies. ""Compared with carriers of the homozygous GG genotype, no significant difference was found in warfarin maintenance doses in all comparisons made""",Genotypes AA + AG is not associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
982044349,rs2359612,VKORC1,warfarin,16611750,Dosage,yes,,Allele G is associated with increased dose of warfarin as compared to allele A.,G,
1448257366,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,27511999,Dosage,yes,in patients after aortic valve replacement within the 3 months of follow up.,CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *3,
1447520081,rs9934438,VKORC1,warfarin,26433837,Dosage,no,"in pediatric patients. No significantly difference was found in any comparisons of VKORC1 1173 genotypes in the meta-analysis (CT versus TT: P = 0.3, WMD = 0.26 [95% CI: -0.23, 0.76]; CC versus TT: P = 0.31, WMD = 1.08 [95% CI: -0.99, 3.14]; C versus TT: P =0.05, WMD = 0.41 [95% CI: 0.0, 0.82]).",Genotypes AG + GG are not associated with decreased dose of warfarin as compared to genotype AA.,AG + GG,Pediatric
1448257356,rs9923231,VKORC1,warfarin,27511999,Dosage,yes,in patients after aortic valve replacement within the 3 months of follow up.,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1449192282,rs1799853,CYP2C9,warfarin,28049362,Dosage,yes,,Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.,CT,
1449192273,rs9923231,VKORC1,warfarin,28049362,"Dosage,""Other""",yes,Please note: alleles have been complemented to the + chromosomal strand.,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1449192290,rs1057910,CYP2C9,warfarin,28049362,Dosage,yes,,Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.,AC,
1448257253,rs2288344,NEDD4,warfarin,27488176,Dosage,yes,"The NEDD4 SNP was associated with an increase of 0.20 mg/week (on square root scale) per minor allele. Adding the new SNPs to a model including VKORC1 (rs9923231), CYP2C9 (*2/*3) and clinical factors increased R2 by 2.9%.",Allele G is associated with increased dose of warfarin as compared to allele T.,G,
1448257237,rs17126068,DDHD1,warfarin,27488176,Dosage,yes,"The DDHD1 SNP was associated with a lowering of dose per minor allele (beta estimate: -0.80 mg/week on square root scale); however, no homozygotes for the minor allele were present. Adding the new SNPs to a model including VKORC1 (rs9923231), CYP2C9 (*2/*3) and clinical factors increased R2 by 2.9%.",Allele G is associated with decreased dose of warfarin as compared to allele A.,G,
1447519925,rs9923231,VKORC1,warfarin,19752777,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1448257212,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,27488176,Dosage,yes,,CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2,
1447519944,rs2359612,VKORC1,warfarin,19752777,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1447519938,rs2860905,CYP2C9,warfarin,19752777,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1447519932,rs1057910,CYP2C9,warfarin,19752777,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1448257202,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,27488176,Dosage,yes,,CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3,
1448109703,rs72558189,CYP2C9,warfarin,27121899,Dosage,not stated,This variant annotation is part of a dosing algorithm table based on 8 genetic variants.,Allele A is associated with dose of warfarin as compared to allele G.,A,
1448109681,rs28371686,CYP2C9,warfarin,27121899,Dosage,not stated,This variant annotation is part of a dosing algorithm table based on 8 genetic variants.,Allele C is associated with dose of warfarin as compared to allele G.,C,
1448109677,rs1057910,CYP2C9,warfarin,27121899,Dosage,not stated,This variant annotation is part of a dosing algorithm table based on 8 genetic variants.,Allele A is associated with dose of warfarin as compared to allele C.,A,
1448257142,rs3815455,POR,warfarin,27488389,Dosage,no,in Han Chinese. This variant is also called POR 830+116C>T.,Genotypes CT + TT is not associated with dose of warfarin as compared to genotype CC.,CT + TT,
1448109663,rs2108622,CYP4F2,warfarin,27121899,Dosage,not stated,This variant annotation is part of a dosing algorithm table based on 8 genetic variants.,Allele C is associated with dose of warfarin as compared to allele T.,C,
1451918940,rs12777823,,warfarin,36210801,Metabolism/PK,yes,"for S-warfarin stereoisomer in particular, measured as increased S-warfarin/R-warfarin ratio and decreased S-7OH-warfarin/S-warfarin and using a Bonferroni-adjusted replication significance threshold p < 3.21 × 10−4.","Allele A is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele G.",A,
1448257102,rs2108622,CYP4F2,warfarin,27488389,Dosage,yes,in Han Chinese.,Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
1451919893,rs558364281,GRID2,"6-hydroxy r-warfarin,""6-hydroxy s-warfarin""",36210801,Metabolism/PK,yes,measured as increased RS-6OH-warfarin and using a genome wide significance threshold of < 3.846 × 10−9.,"Allele G is associated with increased concentrations of 6-hydroxy r-warfarin and 6-hydroxy s-warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele A.",G,
982044655,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,18836275,Dosage,yes,,CYP2C9 *1/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1.,*1/*3,
982044677,"CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,18836275,Dosage,yes,,CYP2C9 *2/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1.,*2/*3,
1448633915,rs1060467,CYP4F11,warfarin,28620303,Dosage,yes,"The G allele was associated with a decrease in stable warfarin dose and accounted for 2.6% of the variance. AA= 4.6 ± 0.2, AG = 3.9 ± 0.1 GG = 3.8 ± 0.2. The addition of rs1060467 to PGx algorithm (included CYP2C9, VKORC1) explained a further 0.5–0.7% of variability. When conditioned on rs1060467, the association w/ rs2108622 & warfarin dose decreased (beta initial = 0.078, beta conditional = 0.063, initial P-value = 0.003, conditional P-value = 0.05). Alleles have been complemented to the positive strand.",Allele G is associated with decreased dose of warfarin as compared to allele A.,G,
1451919000,rs28371685,CYP2C9,warfarin,36210801,Metabolism/PK,yes,"for S-warfarin stereoisomer in particular, measured as increased S-warfarin/R-warfarin ratio and decreased S-7OH-warfarin/S-warfarin and using a Bonferroni-adjusted replication significance threshold p < 3.21 × 10−4. (CYP2C9*11)","Allele T is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele C.",T,
1448633907,rs2108622,CYP4F2,warfarin,28620303,Dosage,yes,"The T allele was associated with increased stable dose (mg/day) of warfarin and explained 4.3% of the variance in dose. CC=3.7±0.1 CT=4.3±0.2 TT=5.3±0.4. The addition of rs2108622 to PGx algorithm (included CYP2C9, VKORC1) explained a further 0.5–0.7% of variability. When conditioned on rs7248867, the association w/ rs2108622 & warfarin dose decreased (beta initial = 0.078, beta conditional = 0.065, initial P-value = 0.003, conditional P-value = 0.015). When conditioned on rs2074568, decrease of magnitude and significance also rs2108622 (beta conditional = 0.069, conditional P-value= 0.009). Suggests that rs7248867 and rs2074568 are correlated with rs2108622.",Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1451919592,rs2256871,CYP2C9,warfarin,36210801,Metabolism/PK,yes,"for S-warfarin stereoisomer in particular, measured as increased S-warfarin/R-warfarin ratio and using a Bonferroni-adjusted replication significance threshold p < 3.21 × 10−4. (CYP2C9*9)","Allele G is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele A.",G,
1451919608,rs11188082,CYP2C19,warfarin,36210801,Metabolism/PK,yes,measured as decreased S-warfarin/R-warfarin ratio and using a genome wide significance threshold of < 3.846 × 10−9. Effect direction from supplementary table S14.,"Allele T is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele A.",T,
1451919880,rs10433340,PARP14,6-hydroxy s-warfarin,36210801,Metabolism/PK,yes,measured as increased S-6OH-warfarin and using a genome wide significance threshold of < 3.846 × 10−9.,"Allele A is associated with increased concentrations of 6-hydroxy s-warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele G.",A,
1451919840,rs368245720,,6-hydroxy s-warfarin,36210801,Metabolism/PK,yes,"measured as increased S-6OH-warfarin and using a genome wide significance threshold of < 3.846 × 10−9. Effect direction from supplementary table S9. There were five SNPs in the same intergenic region on chromosome 10 with same p value (rs368245720, rs541817388, 10:107692518:AC:A, rs112552343, rs372488899).","Allele A is associated with increased concentrations of 6-hydroxy s-warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele T.",A,
1451918980,rs7900194,CYP2C9,warfarin,36210801,Metabolism/PK,yes,"for S-warfarin stereoisomer in particular, measured as increased S-warfarin/R-warfarin ratio and decreased S-7OH-warfarin/S-warfarin and using a Bonferroni-adjusted replication significance threshold p < 3.21 × 10−4. (CYP2C9*8)","Allele A is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele G.",A,
1451919719,rs41291550,CYP2C18,warfarin,36210801,Metabolism/PK,yes,"measured as decreased S-warfarin/R-warfarin ratio and using a genome wide significance threshold of < 3.846 × 10−9. Effect direction from supplementary table S14. Authors note this is ""stop gained coding sequence variant of CYP2C18"".","Allele A is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele T.",A,
1451919700,rs9332241,CYP2C9,warfarin,36210801,Metabolism/PK,yes,"measured as decreased S-warfarin/R-warfarin ratio and using a genome wide significance threshold of < 3.846 × 10−9. Effect direction from supplementary table S14. Authors note this is ""three prime untranslated region variant of CYP2C9, in LD with CYP2C9*8"".","Allele T is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele C.",T,
982047968,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,22130800,Dosage,no,"In univariate analysis the weekly warfarin dose was most strongly associated with age, weight, height, BSA, sex, and VKORC1 genotype. There was a trend of association between the presence of 1 or 2 CYP2C9 variant alleles and decreased dose requirement but the association was not significant (this is the first reported p-value). After statistical adjustment for confounding variables the multivariate analysis showed that CYP2C9 genotype (number of variant * alleles, 0,1,2) explained 2% of the observed inter individual variability in warfarin dose (this is the second reported p-value).",CYP2C9 *2 + *3 are associated with dose of warfarin in children as compared to CYP2C9 *1.,*2 + *3,Pediatric
1447519665,rs9934438,VKORC1,warfarin,18466099,Dosage,yes,in European Americans and African americans.,Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1447519677,rs8050894,VKORC1,warfarin,18466099,Dosage,yes,in European Americans.,Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.,CG + GG,
1446765966,rs10090884,GATA4,warfarin,26257249,Dosage,no,"Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. Please note, alleles have been complimented to the + strand.",Genotype AA is not associated with dose of warfarin as compared to genotypes AC + CC.,AA,
1446765971,rs2917670,NQO1,warfarin,26257249,Dosage,no,"Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. Please note, alleles have been complimented to the + strand.",Genotype CC is not associated with dose of warfarin as compared to genotypes CT + TT.,CC,
1446765943,rs1800566,NQO1,warfarin,26257249,Dosage,yes,"Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. The AA genotype was associated with mean stable warfarin dose in univariate analysis, but did not remain associated in multiple linear analysis. Only after stratifying by VKORC1 rs994438 genotype AA did rs1800566 become significantly associated with warfarin dose. Please note, alleles have been complemented to the + chromosomal strand.",Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
1446765956,rs699664,GGCX,warfarin,26257249,Dosage,no,"Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. Please note, alleles have been complimented to the + strand.",Genotype CC is not associated with dose of warfarin as compared to genotypes CT + TT.,CC,
1446765961,rs12714145,GGCX,warfarin,26257249,Dosage,no,"Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose.",Genotype CC is not associated with dose of warfarin as compared to genotypes CT + TT.,CC,
1446765922,rs1057910,CYP2C9,warfarin,26257249,Dosage,yes,"Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose.",Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.,AC,
1184472447,rs7294,VKORC1,warfarin,20128861,Dosage,yes,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1448568092,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,27878474,Metabolism/PK,yes,"Clearance of S-warfarin was reduced by 25, 39 and 47% among heterozygote for CYP2C9*2 (n = 41), CYP2C9*3 (n = 26) and carriers of 2 variant alleles (n = 14) as compared to CYP2C9*1/*1 carriers.",CYP2C9 *2 + *3 are associated with decreased clearance of warfarin in healthy individuals as compared to CYP2C9 *1/*1.,*2 + *3,
1184472455,"CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5",CYP2C9,warfarin,20128861,Dosage,yes,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",CYP2C9 *3 + *5 + *2 + *1 is associated with dose of warfarin.,*3 + *5 + *2 + *1,
1447519521,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,11926893,Dosage,yes,"Mean maintenance dose varied significantly among the 6 genotype groups (*1/*1 [n = 127], *1/*2 [n = 28], *1/*3 [n = 18], *2/*2 [n = 4], *2/*3 [n = 3], *3/*3 [n = 5]) (by Kruskall-Wallis test, chi(2)(5) = 37.348; P<.001)",CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*2.,*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3,
1447519494,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,18570163,Dosage,yes,,CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3,
1447519445,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,15714076,Dosage,yes,"Mean difference in daily warfarin dose for CYP2C9*2 carriers vs wild type, the reduction was 0.85 mg (0.60-1.11 mg), a 17% reduction.",CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2,
1184472389,rs2108622,CYP4F2,warfarin,20128861,Dosage,no,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele T is not associated with dose of warfarin as compared to allele C.,T,
1447519456,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,15714076,Dosage,yes,"Mean difference in daily warfarin dose for CYP2C9*3 carriers vs wild type, the reduction was 1.92 mg (1.37-2.47 mg), a 37% reduction.",CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3,
1184472404,rs2189784,CYP4F2,warfarin,20128861,Dosage,no,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele A is not associated with dose of warfarin as compared to allele G.,A,
1184472408,rs2290228,CALU,warfarin,20128861,Dosage,no,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele A is not associated with dose of warfarin as compared to allele G.,A,
1184472412,rs11676382,GGCX,warfarin,20128861,Dosage,no,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele C is not associated with dose of warfarin as compared to allele G.,C,
1184472416,rs61742245,VKORC1,warfarin,20128861,Dosage,no,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele A is not associated with dose of warfarin as compared to allele C.,A,
1184472424,rs9923231,VKORC1,warfarin,20128861,Dosage,yes,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
981502435,rs9923231,VKORC1,"acenocoumarol,""warfarin""",19875892,Efficacy,yes,This = VKORC1*2. The 5 low responders were all CC. Required doses were (CC + CT): 5.9+/-1.9 mg and TT: 4.1+/-3.3 mg.,Genotypes CC + CT are associated with increased dose of acenocoumarol or warfarin as compared to genotype TT.,CC + CT,
1447519344,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,23602689,Dosage,not stated,,CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *3,
1451927120,"CYP2C9*1, CYP2C9*46",CYP2C9,warfarin,36303140,Dosage,no,in a case study.,CYP2C9 *1/*46 is associated with decreased dose of warfarin.,*1/*46,
1184472851,rs9923231,VKORC1,warfarin,24474498,Dosage,yes,,Genotype TT is associated with decreased dose of warfarin in children as compared to genotypes CC + CT.,TT,Pediatric
1448567673,rs2189784,CYP4F2,warfarin,28079798,Dosage,yes,,Genotypes AG + GG are associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.,AG + GG,
1184472866,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,24474498,Dosage,no,,CYP2C9 *1/*2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.,*1/*2,Pediatric
1448567667,rs2260863,EPHX1,warfarin,28079798,Dosage,yes,,Genotype CG is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype CC.,CG,
1448567661,rs7412,APOE,warfarin,28079798,Dosage,yes,,Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype CT.,CC,
1448567655,rs28371759,CYP3A4,warfarin,28079798,Dosage,yes,,Genotype AA are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype AG.,AA,
1448567649,rs2069514,CYP1A2,warfarin,28079798,Dosage,yes,,Genotype GG are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype AA.,GG,
1448567637,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,28079798,Dosage,yes,,CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin in people with heart valve replacement as compared to CYP2C9 *1/*1.,*1/*3 + *3/*3,
1448567630,rs9923231,VKORC1,warfarin,28079798,Dosage,yes,,Genotypes CT + TT are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype CC.,CT + TT,
1184472932,rs7089580,CYP2C9,warfarin,24474498,Dosage,yes,,Allele T is associated with decreased dose of warfarin in children as compared to allele A.,T,Pediatric
1447682722,rs1800566,NQO1,warfarin,26745506,Dosage,yes,"The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: 1) the derivation cohort was 99% male 2) alleles have been complemented to the + chromosomal strand and 3) ""variables were included in final lin. reg model if p<0.05 or if association with daily warfarin dose was marginally significant 0.05 = p = 0.20 with strong biological plausability"".",Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.,AA + AG,
1447682700,"CYP4F2*1, CYP4F2*3",CYP4F2,warfarin,26745506,Dosage,yes,"The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male.",CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.,*3,
1447682688,rs9923231,VKORC1,warfarin,26745506,Dosage,yes,"The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male.",Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1450979360,rs17708472,VKORC1,warfarin,25084205,Dosage,yes,"VKORC1*4 variant (mapped to rs17708472 A) was associated with requiring a higher warfarin dose. Linear regression and polynomial regression was used to calculate the contribution of each variable towards therapeutic dose of warfarin, prior to the development of pharmacogenetic algorithms.",Allele A is associated with increased dose of warfarin as compared to allele G.,A,
1447682605,"CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8",CYP2C9,warfarin,26745506,Dosage,yes,"The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male and ""variables were included in final lin. reg model if p<0.05 or if association with daily warfarin dose was marginally significant 0.05 = p = 0.20 with strong biological plausability"".",CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.,*2 + *3 + *8,
1449259246,rs2108622,CYP4F2,warfarin,27617219,Dosage,no,,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1184473273,rs1051741,EPHX1,warfarin,20716240,Dosage,yes,"in Caucasians. However,this SNP was no longer statistically significantly associated with warfarin dosing after accounting for the number of tag SNPS the authors evaluated within the EPHX1 gene.",Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.,CT,
1451340012,"CYP2C9*1, CYP2C9*6",CYP2C9,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, CYP2C9*6 allele is associated with 8.1mg/week less warfarin dose requirement compared to wild-type homozygotes.",CYP2C9 *1/*6 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*6,
1448276267,"CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,25989350,Dosage,not stated,This study assessed the clinical application of genotype-guided dosing of warfarin. The algorithm used to guide dose of warfarin included these variants.,CYP2C9 *2 + *3 are associated with dose of warfarin in people with Stroke.,*2 + *3,
1448112396,rs1057910,CYP2C9,warfarin,26010205,Metabolism/PK,yes,The outcome of this study was the variable rate of fall in the INR in patients withdrawing from warfarin treatment prior to elective surgery. Patients were assessed along with rs1799853. Patients with two variant alleles *2*2 or *2*3 had increased odds of having an INR over 1.5 on the planned surgery.,Genotype CC is associated with decreased clearance of warfarin as compared to genotypes AA + AC.,CC,
1183699285,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,17387222,Dosage,yes,*3 was associated with 38.1 %(95% CI 29.3 -45.7%) reduction in therapeutic dose (defined as the dose that gave an INR in the target therapeutic range after 7 consecutive days) per copy.,CYP2C9 *3 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.,*3,
1448112390,rs1799853,CYP2C9,warfarin,26010205,Metabolism/PK,yes,The outcome of this study was the variable rate of fall in the INR in patients withdrawing from warfarin treatment prior to elective surgery. Patients were assessed along with rs1057910. Patients with two variant alleles *2*2 or *2*3 had increased odds of having an INR over 1.5 on the planned surgery.,Genotype TT is associated with decreased clearance of warfarin as compared to genotypes CC + CT.,TT,
1448276214,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,27763679,Metabolism/PK,yes,The *1/*3 diplotype was associated with increased clearance of R-warfarin but decreased clearance of S-warfarin.,CYP2C9 *1/*3 is associated with clearance of warfarin in people with Heart Diseases as compared to CYP2C9 *1/*1.,*1/*3,
1183699325,rs1799853,CYP2C9,warfarin,17387222,Dosage,yes,T (*2) was associated with 17.4 %(95% CI 8.3-25.6%) reduction in therapeutic dose (defined as the dose that gave an INR in the target therapeutic range after 7 consecutive days) per copy.,Allele T is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele C.,T,
1184469338,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,24019055,Dosage,yes,Genetic variants in CYP2C9 contributed to 12.4% of the variation in warfarin dose.,CYP2C9 *1/*2 is associated with increased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2,
1183699310,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,17387222,Dosage,yes,*2 was associated with 17.4 %(95% CI 8.3-25.6%) reduction in therapeutic dose (defined as the dose that gave an INR in the target therapeutic range after 7 consecutive days) per copy.,CYP2C9 *2 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.,*2,
1448276106,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,27661060,Dosage,yes,Maintenance warfarin doses in pediatric patients with CYP2C9 *1/*3 genotype were 41% lower than doses in patients with the wild type allele (CYP2C9 *1/*1).,CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.,*1/*3,Pediatric
1448276095,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,27661060,Dosage,yes,Maintenance warfarin doses in pediatric patients with CYP2C9 *1/*2 genotype were 15% lower than doses in patients with the wild type allele (CYP2C9 *1/*1).,CYP2C9 *1/*2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.,*1/*2,Pediatric
1448276076,rs9332098,CYP2C9,warfarin,21326313,Dosage,yes,The mean warfarin dose was higher in patients with the GG genotype (3.5+/-2.0 mg/day) as compared to those with the AG genotype (2.5+/-1.0 mg.day).,Genotype GG is associated with increased dose of warfarin as compared to genotype AG.,GG,
1448276066,rs9332092,CYP2C9,warfarin,21326313,Dosage,yes,The mean warfarin dose was higher in patients with the TT genotype (3.5+/-2.0 mg/day) as compared to those with the CT genotype (2.5+/-1.0 mg.day).,Genotype TT is associated with increased dose of warfarin as compared to genotype CT.,TT,
1448275978,rs699664,GGCX,warfarin,21326313,Dosage,yes,"Patients with the CC genotype had a higher mean warfarin dose (3.5+/-2.0 mg/day) as compared to patients with the CT or TT genotype (3.0+/-1.8 and +/-2.0, respectively). Additionally, this variant was included in an algorithm for determining warfarin dose. Please note that alleles have been complemented to the plus chromosomal strand.",Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.,CC,
981239462,rs104894539,VKORC1,warfarin,14765194,Dosage,not stated,This rare (<0.1%) missense mutation in VKORC1 gene confers warfarin resistance phenotype. Individuals carrying this mutation require higher dose of warfarin (14mg/d). VKORC1: V29L; Val29Leu,Allele A is associated with increased dose of warfarin as compared to allele C.,A,
981239505,rs104894541,VKORC1,warfarin,18234403,Dosage,not stated,This rare (<0.1%) missense mutation in VKORC1 gene confers warfarin resistance phenotype. Individuals carrying this mutation require higher dose of warfarin (32-36mg/d). VKORC1:R58G; Arg58Gly,Allele C is associated with increased dose of warfarin as compared to allele T.,C,
981239514,rs104894540,VKORC1,warfarin,18234403,Dosage,not stated,"Allele G (Val45Ala) is associated with severe warfarin resistance, may require a higher dose (INR never reached).",Allele G is associated with increased dose of warfarin as compared to allele A.,G,
981239523,rs104894539,VKORC1,warfarin,18234403,Dosage,not stated,This rare (<0.1%) missense mutation in VKORC1 gene confers warfarin resistance phenotype. Individuals carrying this mutation require higher dose of warfarin (14mg/d). VKORC1: V29L; Val29Leu,Allele A is associated with increased dose of warfarin as compared to allele C.,A,
981239480,rs104894540,VKORC1,warfarin,14765194,Dosage,not stated,"Allele G (Val45Ala) is associated with severe warfarin resistance, may require a higher dose (INR never reached)",Allele G is associated with increased dose of warfarin as compared to allele A.,G,
981239489,rs104894542,VKORC1,warfarin,14765194,Dosage,not stated,Leu128Arg variant confers severe warfarin resistance. Daily dose >45mg,Allele C is associated with increased dose of warfarin as compared to allele A.,C,
981239497,rs104894542,VKORC1,warfarin,18234403,Dosage,not stated,Leu128Arg variant confers severe warfarin resistance. Daily dose >45mg,Allele C is associated with increased dose of warfarin as compared to allele A.,C,
1451408520,rs12777823,,warfarin,28686080,Dosage,yes,"in patients initiating warfarin treatment with a target international normalized ratio (INR) of 2 to 3. Direction of the relationship of allele to dose is not explicitly stated. rs12777823 is described as ""within the CYP2C gene cluster"" and ""upstream from CYP2C18"".",Allele A is associated with dose of warfarin as compared to allele G.,A,
981862284,rs61742245,VKORC1,warfarin,23571513,Dosage,yes,"Egyptian carriers of the VKORC1 rs61742245 A allele (Tyr 36) showed higher warfarin dose requirement (57.1 ± 29.4 mg/week) than those with the CC (Asp36Asp) genotype (35.8 ± 16.6 mg/week; p<0.03). ""This SNP was most frequent among Kenyans and Sudanese, with a minor allele frequency (MAF) of 6% followed by Saudi Arabians and Egyptians with a MAF of 3% and 2.5%, respectively. It was not detected in West Africans (Ghana), and a large cohort of African Americans.""",Genotypes AA + AC are associated with increased dose of warfarin as compared to genotype CC.,AA + AC,
1451409502,rs9923231,VKORC1,warfarin,31902949,Dosage,yes,Please note that alleles have been complemented to the positive strand.,Genotypes CC + CT is associated with increased dose of warfarin in people with Heart Failure as compared to genotype TT.,CC + CT,
1449157673,rs9923231,VKORC1,warfarin,29234073,Dosage,yes,,Genotype TT is associated with decreased dose of warfarin as compared to genotype CC.,TT,
1183700066,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,19031075,Dosage,yes,"Dose reduction was 19.6% (95% CI: 17.4 - 21.9%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1.",CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2,
1448255587,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,27453700,Dosage,not stated,,CYP2C9 *3 is associated with dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1.,*3,Pediatric
1449258301,rs1057910,CYP2C9,warfarin,27617219,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1451516060,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,"phenprocoumon,""warfarin""",20833980,Dosage,no,"in pediatric patients. Referred to in the paper as rs1799853, which is the defining allele of CYP2C9*2, and rs1057910, which is the defining allele of CYP2C9*3.",CYP2C9 *2 + *3 are not associated with dose of phenprocoumon or warfarin as compared to CYP2C9 *1.,*2 + *3,Pediatric
981239905,rs2108622,CYP4F2,warfarin,22871975,Dosage,no,,Allele C is not associated with increased dose of warfarin in people with warfarin maintenance treatment as compared to allele T.,C,
981239887,rs61742245,VKORC1,warfarin,22871975,Dosage,yes,"In carriers of allele A, the weekly warfarin dose was increased by a median of 43.7 mg (IQR, 40.5-47.2 mg) compared to non-carriers. Median weekly dose overall = 35 mg (interquartile range [IQR], 24.5 to 52.5 mg). Also, refinement of the IWPC prediction model to include this variant resulted in significantly better model performance.",Genotype AC is associated with increased dose of warfarin in people with warfarin maintenance treatment as compared to genotype CC.,AC,
1451589723,rs9923231,VKORC1,warfarin,31114289,Dosage,yes,Please note that alleles have been complemented to the positive strand.,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1451589728,rs61742245,VKORC1,warfarin,31114289,Dosage,yes,Please note that alleles have been complemented to the positive strand.,Genotypes AA + AC are associated with increased dose of warfarin as compared to genotype CC.,AA + AC,
1451589737,rs8050894,VKORC1,warfarin,31114289,Dosage,yes,Please note that alleles have been complemented to the positive strand.,Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.,CG + GG,
1451589745,rs2359612,VKORC1,warfarin,31114289,Dosage,yes,Please note that alleles have been complemented to the positive strand.,Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.,AG + GG,
1451589740,rs9934438,VKORC1,warfarin,31114289,Dosage,yes,Please note that alleles have been complemented to the positive strand.,Genotype AA is associated with decreased dose of warfarin as compared to genotypes AC + CC.,AA,
1451589825,rs17708472,VKORC1,warfarin,31114289,Dosage,no,Please note that alleles have been complemented to the positive strand.,Allele A is not associated with dose of warfarin as compared to allele G.,A,
1451589820,rs188009042,VKORC1,warfarin,31114289,Dosage,no,Please note that alleles have been complemented to the positive strand.,Allele C is not associated with dose of warfarin as compared to allele T.,C,
1451589762,rs7294,VKORC1,warfarin,31114289,Dosage,yes,Please note that alleles have been complemented to the positive strand.,Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
1184510128,rs61742245,VKORC1,warfarin,22266406,Dosage,yes,"Individuals carrying the VKORC1 p.Asp36Tyr variant required elevated doses of warfarin (mean 10.0±1.5 mg/d; range 7.1-12.1 mg/d), despite having the low dose VKORC1 c.-1639G>A allele. The VKORC1 p.Asp36Tyr variant explained 10.7% of warfarin dose variability after controlling for VKORC1 c.-1639G>A, CYP2C9 *2 and *3. Inclusion of the warfarin resistant p.Asp36Tyr allele in pharmacogenetic algorithms may be important for clinics with a heterogeneous Caucasian population.",Allele A is associated with increased dose of warfarin as compared to allele C.,A,
1451686520,rs28371686,CYP2C9,warfarin,35108398,Dosage,yes,"Authors describe as ""Without taking CYP2C9*5 into account, the validated pharmacogenetic algorithm overpredicted the warfarin dose by 30% (95% CI [19%-40%], p<0.001), or an average of 1.87 mg/day (SD 1.64) in heterozygotes (p<0.001, Table 3)"". Association of variant and dose is not reported directly.",Genotype CG is associated with decreased dose of warfarin as compared to genotype CC.,CG,
1449157689,rs4149117,SLCO1B3,warfarin,29234073,Dosage,yes,,Genotype GG is associated with decreased dose of warfarin as compared to genotypes GT + TT.,GG,
1451788360,rs9923231,VKORC1,"acenocoumarol,""warfarin""",35608144,Dosage,yes,alleles complemented to plus chromosomal strand (ie effect reported for GA + AA).,Genotypes CT + TT is associated with decreased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype CC.,CT + TT,
1451788400,rs2108622,CYP4F2,"acenocoumarol,""warfarin""",35608144,Dosage,yes,,Genotypes CT + TT is associated with increased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype CC.,CT + TT,
1451788440,rs1057910,CYP2C9,"acenocoumarol,""warfarin""",35608144,Dosage,yes,,Genotypes AC + CC is associated with decreased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype AA.,AC + CC,
1451788412,rs1799853,CYP2C9,"acenocoumarol,""warfarin""",35608144,Dosage,no,no TT were observed.,Genotype CT is not associated with decreased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype CC.,CT,
1448099582,rs112936952,GGCX,warfarin,19582440,Dosage,no,"While the table showed a higher average dose for those with the 10/10 repeat genotype compared to 11 repeats (intermediate) and 12 or 13 repeats, it was not significant.",Allele TTG is not associated with dose of warfarin as compared to genotype TTG/TTGTTGTTG.,TTG,
1449157684,rs1143672,SLC15A2,warfarin,29234073,Dosage,yes,,Genotype AA is associated with decreased dose of warfarin as compared to genotype GG.,AA,
1183701330,rs9934438,VKORC1,warfarin,17989110,Dosage,not stated,Weekly maintenance doses were GG: 42.1 mg; AG: 34.4: AA: 20.7 mg.,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1183701300,rs9923231,VKORC1,warfarin,19679631,"Dosage,""Efficacy""",yes,"The plasma S-warfarin concentration required to yield the target INR response for each genotype: CC, 0.68 mg/L; TC, 0.48 mg/L; TT, 0.27 mg/L.",Allele T is associated with increased response to warfarin as compared to allele C.,T,
1183701524,rs9923231,VKORC1,warfarin,20421126,Dosage,yes,"The study purpose was to develop a model for stable maintenance warfarin dose prediction. Most patients had a history of venous thromboembolism. TT patients required a lower dose than TC patients, who required a lower dose than CC patients.",Allele T is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele C.,T,
769277903,rs7294,"PRSS53,""VKORC1""",warfarin,15358623,Dosage,yes,,Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.,TT,
1447520074,rs9923231,VKORC1,warfarin,26433837,Dosage,yes,in pediatric patients.,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,Pediatric
827654491,rs9934438,VKORC1,warfarin,17111199,Dosage,yes,,Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1444694676,rs7294,VKORC1,warfarin,25594941,Dosage,no,"158/220 patients had the target INR (1.5–2.5). The comparison of weekly warfarin maintenance dose was significantly different among patients of different genotypes: GGCX rs7294 (CC 19.40±5.75 mg/w vs CT 27.87±8.80 mg/w p < 0.001 ANOVA). The allele was not significantly associated with weekly maintenance dose when analyzed in multiple linear regression analysis, however.",Genotype CC is not associated with dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.,CC,
1184472429,rs9934438,VKORC1,warfarin,20128861,Dosage,yes,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1184472436,rs2359612,VKORC1,warfarin,20128861,Dosage,yes,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1184472420,rs17708472,VKORC1,warfarin,20128861,Dosage,no,"Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.",Allele A is not associated with dose of warfarin as compared to allele G.,A,
1446847493,rs9923231,VKORC1,warfarin,26219158,Dosage,yes,in Thai patients.,Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1450979020,rs9934438,VKORC1,warfarin,21127708,"Dosage,""Efficacy""",yes,"This is shown for *2/*2, *2/*3 and *2/*4 vs *3/*3, *3/*4 and *4/*4. Authors define *2 as VKORC1*2 (rs9934438/6484 C > T). Alleles complemented.",Genotypes AA + AG is associated with decreased dose of warfarin in people with Myocardial Infarction as compared to genotype GG.,AA + AG,
1450979180,rs9923231,VKORC1,warfarin,17387222,Dosage,yes,"Haplotype A (defined by rs9923231A and elsewhere defined to = H1 and H2) was associated with 10.7%(95% CI 2.0 - 18.6%) reduction in therapeutic dose (defined as the dose that gave an INR in the target therapeutic range after 7 consecutive days) per copy as compared to ""Haplotype B"" (defined as H7,H8,H9 elsewhere). There were 4 patients missing data for rs9923231, and for these cases haplotype was based on rs8050894 on the basis of high pairwise linkage disequilibrium.",Allele A is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele G.,A,
1448255569,rs9923231,VKORC1,warfarin,27453700,Dosage,not stated,,Allele G is associated with dose of warfarin in children with Heart Diseases.,G,Pediatric
1450979280,rs7294,VKORC1,warfarin,25084205,Dosage,yes,"VKORC1*3 variant (mapped to rs7294 T) was associated with requiring a lower warfarin dose. Linear regression and polynomial regression was used to calculate the contribution of each variable towards therapeutic dose of warfarin, prior to the development of pharmacogenetic algorithms.",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1446765916,rs9934438,VKORC1,warfarin,26257249,Dosage,yes,"Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. Please note, alleles have been complimented to the + strand.",Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
1448275994,rs9934438,VKORC1,warfarin,21326313,Dosage,yes,"The mean warfarin dose was higher in patients with the GG genotype (5.0+/-0.0 mg/day) as compared to those with the AA genotype (3.0+/-1.5 mg.day). Additionally, this variant was included in an algorithm for determining warfarin dose. This variant was in linkage disequilibrium with rs7294, rs2359612 and rs8050894. Please note that alleles have been complemented to the plus chromosomal strand.",Genotype GG is associated with increased dose of warfarin as compared to genotype AA.,GG,
1184748906,rs9923231,VKORC1,warfarin,25084205,Dosage,yes,"Variant described as -1639G>A (alleles have been complemented to the plus chromosomal strand). This variant was associated with requiring a lower warfarin dose. Linear regression and polynomial regression was used to calculate the contribution of each variable towards therapeutic dose of warfarin, prior to the development of pharmacogenetic algorithms.",Allele T is associated with decreased dose of warfarin.,T,
981483977,rs9923231,VKORC1,warfarin,20653676,"Dosage,""Efficacy""",yes,2.6 mg/day vs 4.0 mg/day.,Genotype TT is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to genotypes CC + CT.,TT,
981500585,rs7294,VKORC1,warfarin,21127708,"Dosage,""Efficacy""",no,"This is VKORC1*3. There was a significant association when analyzed alone, but the effect was so small that it was negligible when analyzed with VKORC1*2,CYP2C9*2 and CYP2C9*3.",Allele T is associated with increased dose of warfarin in people with Myocardial Infarction as compared to allele C.,T,
827642001,rs9934438,"PRSS53,""VKORC1""",warfarin,17329985,Dosage,yes,in african americans.,Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
981500592,rs17708472,VKORC1,warfarin,21127708,"Dosage,""Efficacy""",no,"This is VKORC1 *4. There was a significant association when analyzed alone, but the effect was so small that it was negligible when analyzed with VKORC1*2,CYP2C9*2 and CYP2C9*3.",Allele A is associated with increased dose of warfarin in people with Myocardial Infarction as compared to allele G.,A,
1450370821,rs3093153,CYP4F2,warfarin,30821933,Dosage,no,in Alaska Native and American Indian People.,Allele C is not associated with dose of warfarin as compared to allele A.,C,
1183701155,rs9923231,VKORC1,warfarin,18574025,Dosage,yes,This SNP explained 29% (P = 1.03 x 10(-97)) of the variation in warfarin dose.,Allele T is associated with decreased dose of warfarin.,T,
1183701268,rs2359612,VKORC1,warfarin,18574025,Dosage,yes,This SNP explained 30% (P = 9.82 x 10(-100)) of the variation in warfarin dose. The direction of the allele:dose relationship is not stated.,Allele A is associated with dose of warfarin.,A,
1448601916,rs9934438,VKORC1,warfarin,27938396,Dosage,yes,,"Genotype AG is associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype GG.",AG,
1183697213,rs9923231,VKORC1,warfarin,22349464,Dosage,yes,"This SNP was presented as VKORC1 -1639 G>A. This study endeavored to make a pharmacogenetic algorithm for warfarin dosing. This included two groups, a derivation group and a validation group. In both groups, a significant gene-dose effect was observed as follows: GG>AG>AA. The algorithm used was: Square root of daily dose (mg) = 0.833 - 0.255 (0 for female, 1 for male gender) - 0.007 (age, years) + 0.011 (height, cm) + 0.005 (weight, kg) + 0.385 (smoking, 0=no, 1=yes) + 0.211 (vegetable intake, 0=no, 1=yes) + 0.119 (indication for OAT=VTE, 0=no, 1=yes) + 0.328 (diabetes, 0=no, 1=yes) - 0.458 (variant alleles of CYP2C9, 0, 1, or 2) - 0.571 (VKORC1 -1639 G>A, GG=0, GA=1, AA=2) + 0.025 (VKORC1 3730 G>A, GG=0, GA=1, AA=2). This algorithm underperformed most other published algorithms when determining dose for patients needing doses lower than 44 mg/week, but outperformed all other algorithms when determining dose for patients needing doses greater than or equal to 45 mg/week.",Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.,TT,
1183697222,rs7294,VKORC1,warfarin,22349464,Dosage,yes,"This SNP was presented as VKORC1 3730 G>A. This study endeavored to make a pharmacogenetic algorithm for warfarin dosing. This included two groups, a derivation group and a validation group. In both groups, a significant gene-dose effect was observed as follows: AA>AG>GG. The algorithm used was: Square root of daily dose (mg) = 0.833 - 0.255 (0 for female, 1 for male gender) - 0.007 (age, years) + 0.011 (height, cm) + 0.005 (weight, kg) + 0.385 (smoking, 0=no, 1=yes) + 0.211 (vegetable intake, 0=no, 1=yes) + 0.119 (indication for OAT=VTE, 0=no, 1=yes) + 0.328 (diabetes, 0=no, 1=yes) - 0.458 (variant alleles of CYP2C9, 0, 1, or 2) - 0.571 (VKORC1 -1639 G>A, GG=0, GA=1, AA=2) + 0.025 (VKORC1 3730 G>A, GG=0, GA=1, AA=2). This algorithm underperformed most other published algorithms when determining dose for patients needing doses lower than 44 mg/week, but outperformed all other algorithms when determining dose for patients needing doses greater than or equal to 45 mg/week.",Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.,TT,
1450981800,rs17708472,VKORC1,warfarin,22676192,"Dosage,""Metabolism/PK""",not stated,"in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664). Direction of variant allele to relationship not explicitly stated in paper, haplotype name is used. Alleles complemented to plus chromosomal strand.",Allele A is associated with increased dose of warfarin as compared to allele G.,A,
1183697701,rs7294,VKORC1,warfarin,23990957,Dosage,yes,"This SNP was presented as VKORC1 3730G>A. Patients carrying the T allele showed significantly higher doses of warfarin as compared to patients with the wildtype genotype, CC.",Genotypes CT + TT is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to genotype CC.,CT + TT,
1449164026,rs4760658,VDR,warfarin,29298995,Dosage,yes,"This SNP is in very tight linkage disequilibrium with rs11168293 and rs11168292 (r2>0.97). Mean dose (in mg) of warfarin according to genotype was: GG>AG>AA. p-value adjusted for CYP2C9 metabolizer status and VKORC1 activity status phenotypes, among other factors. Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation.",Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.,GG,
1450180271,rs202201137,CYP2C9,warfarin,30518301,Dosage,no,"in a single individual who also had ""factors like the advanced age of the patient, liver function, co-morbidities, drug-to-drug interactions and the presence of other polymorphisms (CYP2C9*2 and CYP2C9*5) """,Allele G is associated with decreased dose of warfarin.,G,
982047897,rs9923231,VKORC1,warfarin,22130800,Dosage,yes,Children with at least one variant VKORC1 allele required significantly decreased doses as compared with wild type patients. Weekly maintenance doses in wild type patients (CC) were significantly higher (32 mg) than heterozygotes (CT) (23 mg) and individuals with two variant alleles (TT) (10.6 mg). In a multivariate analysis VKORC1 genotype accounted for 18.2% of the interindividual variability observed with warfarin dose. Alleles have been complemented to the plus chromosomal strand.,Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CC.,TT,Pediatric
1183699109,rs9934438,VKORC1,warfarin,19177029,Dosage,yes,"Mean stable dose for AA patients was 2.58 +/- 0.84 mg/day. For AG patients, the mean stable dose was 4.18 +/- 1.34 mg/day, and for GG patients, mean stable dose was 4.53 +/- 0.94 mg/day.",Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
1450980680,rs2359612,VKORC1,warfarin,18322281,Dosage,yes,"With *1/*2 (AG) requiring intermediate dose. This was most marked at day 28 to end of follow-up with average doses of 3.66mg/day for *2*2 (HaplotypeA/HaplotypeA""), 4.45mg/day for HaplotypeA/nonA and 5.68mg/day for nonA/nonA. Authors also used rs9923231, rs2884737, rs9934438, and rs8050894 to define HaplotypeA.",Genotype AA is associated with decreased dose of warfarin as compared to genotype GG.,AA,
1184482753,rs9923231,VKORC1,warfarin,23949431,Dosage,yes,in Han-Chinese patients with mechanical heart valve replacement.,Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1449577151,rs9923231,VKORC1,warfarin,29781049,Efficacy,yes,"The authors evaluated the effects of the alleles in patients who had left ventricular assist devices implanted and were on warfarin. Patients were evaluated in two periods: immediately after LVAD implantation (period 1) immediately prior to hospital discharge (period 2). Times in therapeutic range (TTR) was used as a measure of efficacy. Warfarin sensitivity index (WSI) is defined as the mean prothrombin time-international normalized ratio (PT-INR) divided by the mean daily warfarin dosage, and is indicative of reactivity to anticoagulation by warfarin.","Genotype CT is associated with decreased response to warfarin in people with Ventricular Dysfunction, Left as compared to genotype TT.",CT,
1449577174,rs9923231,VKORC1,warfarin,29781049,Efficacy,yes,The authors evaluated the effects of the alleles in patients who had left ventricular assist devices implanted and were on warfarin. Patients were evaluated in two periods: immediately after LVAD implantation (period 1) immediately prior to hospital discharge (period 2).,"Genotype CT is associated with increased dose of warfarin in people with Ventricular Dysfunction, Left as compared to genotype TT.",CT,
827925119,rs9923231,VKORC1,warfarin,22528326,Dosage,yes,"No CC homozygotes were observed (described as GG in paper complemented to minus chromosomal strand here). Daily maintenance dose range for TT was 2.74 to 3.16mg/day, dose range for CT was 3.61 to 4.51mg/day.",Genotype CT is associated with increased dose of warfarin in people with Thromboembolism as compared to genotype TT.,CT,
1184169091,rs9934438,VKORC1,warfarin,24728385,Dosage,yes,"The goal of this study was to compare the accuracy of 8 different warfarin dosing algorithms, including the IWPC, and 6 Han Chinese PGx warfarin dosing algorithms, in Han Chinese patients taking warfarin scheduled to undergo mechanic heart valve replacement surgery. The authors concluded that the mean absolute error (MAE) of all algorithms was less than 0.6mg/day in initial and stable doses, and the percentage of patients whose actual doses were within 20% of their predicted dose was 45% in all algorithms. Predictive power of algorithms was highest for patients in the ideal-dose range and lowest for patients in the low and high dose range. The most accurate predictions came from three Han-Chinese PGx warfarin dosing algorithms (Du et al. 2010, Huang et al. 2009, Miao et al. 2007).",Genotype AA is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes AG + GG.,AA,
1449577793,rs7196161,VKORC1,warfarin,17015052,Dosage,not stated,as part of a model estimating mean daily warfarin requirements in milligrams per day. Alleles complemented to plus chromosomal strand.,Allele G is associated with dose of warfarin as compared to allele A.,G,
1449577814,rs7196161,VKORC1,warfarin,29986700,Dosage,not stated,used in a study comparing genotype-guided dosing vs conventional for warfarin initiation. Alleles complemented to plus chromosomal strand. Direction of effect not explicitly stated.,"Allele A is associated with dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism, Stroke and Venous Thrombosis as compared to allele G.",A,
1449005283,rs9923231,VKORC1,warfarin,28689179,Dosage,yes,"CYP2C9 and VKORC1 variants are analyzed together to divide patients into three warfarin sensitivity types (normal, sensitive and highly sensitive). ""Warfarin sensitive and highly sensitive responders had heparin therapy discontinued earlier (p<0.001), had a decreased final weekly warfarin dose (p<0.001), spent more time over-anticoagulated (p<0.001) and had an increased bleeding risk with warfarin (sensitive responders HR 1.38 [95% CI 1.11 to 1.71], p=0.0035; highly sensitive responders 1.79 [1.09 to 2.99]; p=0.0252).""",Genotype TT is associated with decreased dose of warfarin in people with venous thromboembolism as compared to genotype CC.,TT,
1448267977,rs9934438,VKORC1,warfarin,21981797,Dosage,yes,"Patients with the AA genotype had significantly lower warfarin doses as compared to patients with the AG or GG genotypes. Additionally, this study developed a pharmacogenetic algorithm for warfarin dosing in Korean patients and then compared it against other pharmacogenetic algorithms; this variant was present in the algorithm. Please note that alleles have been complemented to the plus chromosomal strand.",Genotype AA is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotypes AG + GG.,AA,
1184756163,rs7294,VKORC1,warfarin,25126975,Dosage,yes,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model."" rs7294 remained significantly associated with warfarin maintenance dose in the multivariate analysis.",Allele T is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.,T,
827567282,rs9923231,VKORC1,warfarin,15883587,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
827845768,rs9934438,VKORC1,warfarin,22248286,Dosage,yes,with an international normalized ratio (INR) of 2.0-3.0. This SNP was in LD with rs7294 which was also significantly associated with warfarin-maintenance dose (but rs9934438 was chosen for further analysis).,Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.,AG + GG,
1184511615,rs9934438,VKORC1,warfarin,25026456,Dosage,yes,in Korean patients with prosthetic cardiac valves.,Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
1444694728,rs9923231,VKORC1,warfarin,25594941,Metabolism/PK,yes,"130 plasma samples were obtained 12 hours after the last dose of warfarin. The plasma warfarin concentrations of these samples were comparing plasma concentration within the group of patients with INR between 1.5–2.5 (n = 92) between genotype groups. rs9923231 was associated with a significant reduction of warfarin plasma concentration ( genotype AA 1117.29±323.23 ng/ml vs genotype AG 1675.73±431.09 ng/ml, p < 0.001). rs9923231 was not included in the multiple linear regression analysis because of collinearity. Patients were grouped according to INR and genotypes and those with the G allele needed a higher plasma concentration to achieve the similar goal INR.",Genotype TT is associated with decreased concentrations of warfarin in people with as compared to genotype CT.,TT,
1444694686,rs7294,VKORC1,warfarin,25594941,Dosage,yes,"130 plasma samples were obtained 12 hours after the last dose of warfarin. rs7294 was associated with a significant reduction of warfarin plasma concentration (rs7294: CC 1117.29±323.23 ng/ml vs CT 1675.73±431.09 ng/ml, p < 0.001 ANOVA). rs7294 had significant effects on plasma concentration of warfarin (coefficient was 0.527, p < 0.001) and it could explain 26.7% of the variability in plasma concentration.The plasma warfarin concentrations of these samples were comparing plasma concentration within the group of patients with INR between 1.5–2.5 (n = 92). Patients were grouped according to INR and genotypes. For patients genotype CT or TT a higher plasma concentration was needed to achieve the goal INR.",Genotype CC is associated with decreased concentrations of warfarin in people with heart valve replacement as compared to genotypes CT + TT.,CC,
1184511950,rs9923231,VKORC1,warfarin,24029542,Dosage,yes,"Those with the CC genotype required a higher median cumulative therapeutic dose of warfarin to reach the target international normalized ratio (INR), as compared to those with the TT and CT genotype. 7% of the variability in dose was attributable to VKORC1 rs9923231 genotype. Additionally, subjects who had a TT or CT genotype and a CYP2C9 intermediate or poor metabolizer (IM/PM) genotype required the fewest days to reach target anticoagulation intensity (p=0.01) and the lowest median cumulative therapeutic dose of warfarin to reach the target international normalized ratio (INR) (p=0.007), as compared against patients with the CC + extensive metabolizer (EM), CT + EM and CC + IM/PM (specifically *1/*8 and *2/*3) genotypes. Please note alleles have been complemented to the plus chromosomal strand.",Genotype CC is associated with increased dose of warfarin in healthy individuals as compared to genotypes CT + TT.,CC,
637880240,rs9923231,VKORC1,warfarin,19300499,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
637879816,rs9934438,VKORC1,warfarin,20203262,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1448268958,rs9923231,VKORC1,warfarin,24251363,Dosage,not stated,Study undertaking a randomized trial of genotype-guided dosing of warfarin. The algorithms that the study used to calculate loading dose and dose revision on day 4 or 5 of treatment included this variant.,Genotypes CT + TT is associated with dose of warfarin in people with Atrial Fibrillation and venous thromboembolism.,CT + TT,
1448104695,rs9923231,VKORC1,warfarin,27262824,Dosage,yes,,Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CT.,TT,Pediatric
1450942220,rs9923231,VKORC1,warfarin,31854268,Dosage,yes,"Note Annotation is taken from text description of relationship, although text describes GG as wild-type but table 1 shows it as minor allele. ""For VKORC1 rs9923231, patients with GG wild-type (4.17 ± 0.72 mg/d) required a significant higher warfarin dose than those with GA and AA genotype (3.89 ± 1.29 mg/d, p < 0.05; 2.55 ± 0.91 mg/d, p < 0.001, respectively). "" However, Figure 1B shows bar graph for AA, GA and CG genotypes where CG is likely meant to be GG.","Genotype GG is associated with increased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to genotypes AA + AG.",GG,
1184509863,rs9923231,VKORC1,warfarin,22854539,Dosage,yes,Please note that alleles have been complemented to the plus chromosomal strand.,Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1448109670,rs1799853,CYP2C9,warfarin,27121899,Dosage,not stated,This variant annotation is part of a dosing algorithm table based on 8 genetic variants.,Allele C is associated with dose of warfarin as compared to allele T.,C,
1184510103,rs9923231,VKORC1,warfarin,22274142,Dosage,yes,"This variant is analyzed along with CYP2C9 variants *2, *3, *5.",Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1451120169,rs9923231,VKORC1,warfarin,31395958,Dosage,yes,Please note that alleles have been complemented to the positive strand. Variant referred to in the paper as VKORC1-G1639A.,Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.,TT,
1448106998,rs2359612,VKORC1,warfarin,18030307,Dosage,yes,Allele A is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele G.,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1183704904,rs7294,VKORC1,warfarin,24019055,Dosage,yes,"Seven SNPs in VKORC1 were in strong LD: rs7294, rs2359612, rs8050894, rs9934438, rs2884737, rs9923231, rs7196161. Haplotype ACGCTGT had the highest frequency (0.74) and was associated with the second highest mean daily dose (5.46 mg/day) while the GCGCTGT haplotype (0.09 frequency) was associated with the highest mean daily dose (5.83 mg/day). The authors report that genetic variants in VKORC1 accounted for 32.4% of the variability in warfarin dose.",Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.,CC,
1183700115,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,19031075,Dosage,yes,"Dose reduction was 56.7% (95% CI: 49.1 - 64.3%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1.",CYP2C9 *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2/*3,
1183700123,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,19031075,Dosage,yes,"Dose reduction was 78.1% (95% CI: 72.0 - 84.3%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1.",CYP2C9 *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3/*3,
1183700096,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,19031075,Dosage,yes,"Dose reduction was 33.7% (95% CI: 29.4 - 38.1%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1.",CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3,
1183700106,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,19031075,Dosage,yes,"Dose reduction was 36.0% (95% CI: 29.9 - 42.0%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1.",CYP2C9 *2/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2/*2,
769160740,rs8050894,VKORC1,warfarin,16270629,Dosage,yes,It is in strong linkage disequilibrium (r2>0.9) with rs9923231.,Allele G is associated with decreased dose of warfarin as compared to allele C.,G,
827641894,rs1799853,CYP2C9,warfarin,19300499,"Dosage,""Metabolism/PK""",yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
827641885,rs2108622,CYP4F2,warfarin,19300499,Dosage,yes,,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1184748929,rs2108622,CYP4F2,warfarin,25084205,Dosage,yes,"Variant described as V433M. This variant was associated with requiring a higher warfarin dose. Alleles have been complemented to the plus chromosomal strand - the T allele represents M. Linear regression and polynomial regression was used to calculate the contribution of each variable towards therapeutic dose of warfarin, prior to the development of pharmacogenetic algorithms.",Allele T is associated with increased dose of warfarin.,T,
1449190777,rs11676382,GGCX,"acenocoumarol,""warfarin""",29432897,"Dosage,""Metabolism/PK""",no,,Allele G is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.,G,
1449190764,rs7412,APOE,"acenocoumarol,""warfarin""",29432897,Dosage,no,,Allele C is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele T.,C,
1449190771,rs2108622,CYP4F2,"acenocoumarol,""warfarin""",29432897,Dosage,no,,Allele T is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.,T,
1449190785,rs1045642,ABCB1,"acenocoumarol,""warfarin""",29432897,Dosage,no,,Allele A is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele G.,A,
1184748897,CYP2C9*3,CYP2C9,warfarin,25084205,Dosage,yes,"This variant was associated with requiring a lower warfarin dose. Linear regression and polynomial regression was used to calculate the contribution of each variable towards therapeutic dose of warfarin, prior to the development of pharmacogenetic algorithms.",CYP2C9 *3 is associated with decreased dose of warfarin.,*3,
981483987,rs7294,VKORC1,warfarin,20653676,"Dosage,""Efficacy""",yes,,Genotypes CT + TT are associated with increased dose of warfarin in people with mechanical heart valve replacement as compared to genotype CC.,CT + TT,
1450370504,rs9923231,VKORC1,warfarin,30821933,Dosage,yes,"in Alaska Native and American Indian People. This variant -1639G>A is significantly associated with stable warfarin dose, decreasing the dose required to achieve therapeutic INR by 1.7 mg/day per allele (t-test of coefficients, unadjusted P = 1.4e-05, Bonferroni adjusted P = 7.0e-05).",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
981483967,rs2108622,CYP4F2,warfarin,20653676,"Dosage,""Efficacy""",yes,3.2 mg/day vs. 2.9 mg/day. There were only 15 TT patients.,Genotypes CT + TT are associated with increased dose of warfarin in people with mechanical heart valve replacement as compared to genotype CC.,CT + TT,
1449190935,rs1057910,CYP2C9,warfarin,29432897,Dosage,yes,Dose was weekly dose corrected for weight in kg.,Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele A.,C,
1183700587,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,10509530,"Dosage,""Efficacy""",yes,"The mean dose of warfarin required to achieve target INR was 2.85 mg/day(SD 1.07) for *3 carriers vs 4.10 mg/day(SD 1.51) for ""wild-type"".",CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in men as compared to CYP2C9 *1/*1.,*1/*3 + *3/*3,
1447586737,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,20339978,Dosage,yes,,CYP2C9 *1/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3 + *2/*3,
1447586752,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,20339978,Dosage,no,,CYP2C9 *1/*2 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2,
1450370763,rs9934438,VKORC1,warfarin,30821933,Dosage,yes,"in Alaska Native and American Indian People. This variant -1639G>A is significantly associated with stable warfarin dose, decreasing the dose required to achieve therapeutic INR by 1.7 mg/day per allele (t-test of coefficients, unadjusted P = 1.4e-05, Bonferroni adjusted P = 7.0e-05). This variant is in complete LD with rs9923231.",Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
827642014,rs9934438,VKORC1,warfarin,17329985,Dosage,yes,in Caucasians.,Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1447586674,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,20386359,Dosage,not stated,,CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *3,
981500599,rs2108622,CYP4F2,warfarin,21127708,"Dosage,""Efficacy""",no,"This SNP showed a weak but not significant association with dosage when analyzed alone, and when analyzed with CYP2C9*2,CYP2C9*3 and VKORC1*2, also provided no significant contribution.",Allele C is not associated with dose of warfarin in people with Myocardial Infarction as compared to allele T.,C,
1450370787,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,30821933,Dosage,no,in Alaska Native and American Indian People.,CYP2C9 *3 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3,
1450370774,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,30821933,Dosage,no,in Alaska Native and American Indian People.,CYP2C9 *2 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2,
1447586694,rs9923231,VKORC1,warfarin,20386359,Dosage,not stated,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1183700775,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,17851566,Dosage,yes,Patients carrying a single variant allele (*2 or *3) required 77% of the dose required by *1/*1 patients(p < 0.03). Patients carrying two variant alleles required 52% of the *1/*1 dose (p < 0.001).,CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3,
1450370804,rs2189784,CYP4F2,warfarin,30821933,Dosage,no,in Alaska Native and American Indian People.,Allele G is not associated with dose of warfarin as compared to allele A.,G,
1183700748,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,20375999,Dosage,yes,Each CYP2C9*3 allele resulted in a 28% (23-32%) decrease in therapeutic dose on Day 4 or 5 of therapy.,CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*3,
1450370798,rs11676382,GGCX,warfarin,30821933,Dosage,no,in Alaska Native and American Indian People.,Allele G is not associated with decreased dose of warfarin as compared to allele C.,G,
1183700756,rs9923231,VKORC1,warfarin,20375999,Dosage,yes,Each T allele resulted in a 20% (17-23%) decrease in therapeutic dose on Day 4 or 5 of therapy.,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
827641903,rs1057910,CYP2C9,warfarin,19300499,"Dosage,""Metabolism/PK""",yes,,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1450370833,rs8104361,CYP4F11,warfarin,30821933,Dosage,no,in Alaska Native and American Indian People.,Allele A is not associated with dose of warfarin as compared to allele G.,A,
1183700824,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,17851566,Metabolism/PK,yes,"Patients carrying a single variant allele (*2 or *3) had mean oral clearance of 2.96 +/- 1.67 ml/min, compared to 4.03 +/- 2.19 ml/min in *1/*1 patients (p < 0.02). Patients carrying two variant alleles had mean oral clearance of 0.98 +/- 0.41 ml/min, as compared to 4.03 +/- 2.19 ml/min for *1/*1 patients (p < 0.001).",CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3,
1448602262,rs2108622,CYP4F2,warfarin,27938396,Dosage,no,,"Genotypes CT + TT is not associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.",CT + TT,
1183700910,"CYP2C9*1, CYP2C9*8",CYP2C9,warfarin,19663669,Dosage,yes,"An African-American male previously typed as *1/*1 but whose therapeutic warfarin dose was low (14.4 mg/wk) was sequenced and found to be *8/*8. Out of 600 African American alleles genotyped, the frequency of *8 was 0.047 .",CYP2C9 *8/*8 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*8/*8,
1446767165,rs10517,NQO1,warfarin,26257249,Dosage,yes,"Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. After stratifying for VKORC1 rs994438 AA genotype the SNP was also significant. Please note, alleles have been complemented to the + chromosomal strand.",Genotype GG is associated with decreased dose of warfarin as compared to genotypes AA + AG.,GG,
1449191473,rs2108622,CYP4F2,warfarin,29252193,Dosage,yes,"Patients were divided into two groups: those who required more than 5 mg/day of warfarin (Group B) and those who required less than 5 mg/day of warfarin (Group A). Within Group B, the frequency of the T allele was 44% vs. 30% in Group A.",Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.,T,
1183701116,CYP2C9*3,CYP2C9,warfarin,18574025,Dosage,yes,CYP2C9*2 and *3 explained 12% (P = 6.63 x 10(-34)) of the variation in warfarin dose.,CYP2C9 *3 is associated with decreased dose of warfarin.,*3,
1183701108,CYP2C9*2,CYP2C9,warfarin,18574025,Dosage,yes,CYP2C9*2 and *3 explained 12% (P = 6.63 x 10(-34)) of the variation in warfarin dose.,CYP2C9 *2 is associated with decreased dose of warfarin.,*2,
1447520668,rs72547529,VKORC1,warfarin,26513304,Efficacy,not stated,"28-year-old Tanzanian man received enoxaparin 80 mg twice daily and warfarin. The warfarin dose was titrated up to 21 mg daily, but after 4 weeks, the international normalized ratio was subtherapeutic at 1.8. A variation (G>A, negative strand) in the VKORC1 gene was found, resulting in the substitution of Val with Met at residue 66 (Val66Met).",Allele T is associated with decreased response to warfarin as compared to allele C.,T,
827690618,rs1131873,EPHX1,warfarin,21593757,Dosage,no,in italian patients.,Allele A is not associated with dose of warfarin.,A,
1183701285,rs3814637,CYP2C19,warfarin,18574025,Dosage,yes,This SNP explained 0.7% (P = 2.2 x 10(-6)) of the variation in warfarin dose. The direction of the allele:dose relationship is not given.,Allele C is associated with dose of warfarin.,C,
1183701274,rs4917639,CYP2C9,warfarin,18574025,Dosage,yes,This SNP explained 12% (P = 4.61 x 10(-30)) of the variation in warfarin dose. The direction of the allele:dose relationship is not given.,Allele A is associated with dose of warfarin.,A,
827657784,rs1799853,CYP2C9,warfarin,17111199,Dosage,yes,,Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.,CT,
1448573185,rs4889606,STX1B,warfarin,28135054,Dosage,yes,"in African american patients even after conditioning on VKORC1 -1639G>A (rs9923231) variant. ""Inclusion of rs4889606 genotypes, along with CYP2C9 alleles, rs9923231 genotypes, and clinical variables explained 31% of the interpatient variability in warfarin dose requirement."" ""The daily warfarin dose was significantly different among the three genotypes of rs4889606 with carriers of the AG or GG genotypes requiring higher doses (6.8 ±3.1 mg/day and 7.6 ±3.9 mg/day, respectively) compared to AA carriers in the Discovery (ß = 1.1; 95%CI = 0.46 – 1.8, p = 0.0009)"".",Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.,AG + GG,
1450981840,rs7294,VKORC1,warfarin,22676192,"Dosage,""Metabolism/PK""",not stated,"in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664). Direction of variant allele to relationship not explicitly stated in paper, haplotype name is used. Alleles complemented to plus chromosomal strand.",Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1444608072,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,25312789,Dosage,yes,"This is using Classification I. It divided the individuals into three dose ranges: <=21 mg, 21–49 mg, and >= 49 mg/week.",CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*3,
1184483798,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,23104259,Dosage,yes,,CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3 + *3/*3,
1184483809,rs9923231,VKORC1,warfarin,23104259,Dosage,yes,,Genotypes CC + CT is associated with increased dose of warfarin as compared to genotype TT.,CC + CT,
1184483813,rs2108622,CYP4F2,warfarin,23104259,Dosage,yes,,Genotype TT is associated with increased dose of warfarin as compared to genotype CC.,TT,
1183697679,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,23990957,Dosage,yes,"Patients with the *2 or *3 alleles showed significantly lower doses (17% or 32%, respectively) of warfarin as compared to patients with the wildtype genotype (*1/*1). When studied together with VKORC1 1639G/A, patients carrying variants in both genes needed between 34.8% and 84% of the dose needed for patients wildtype for both genes.",CYP2C9 *2 + *3 are associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.,*2 + *3,
1183697690,rs9923231,VKORC1,warfarin,23990957,Dosage,yes,"A gene-dose effect was seen in that dose of warfarin decreased with the presence of the T allele: CC>CT>TT. When studied together with CYP2C9, patients carrying variants in both genes needed between 34.8% and 84% of the dose needed for patients wildtype for both genes.",Genotype TT is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotypes CC + CT.,TT,
1447573274,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,19074728,Dosage,yes,,CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *3,
655387565,rs1799853,CYP2C9,warfarin,19228618,Dosage,no,,Allele T is associated with decreased dose of warfarin.,T,
827658659,rs1057910,CYP2C9,warfarin,17111199,Dosage,yes,,Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.,AC,
655387562,rs1057910,CYP2C9,warfarin,19228618,Dosage,no,,Allele C is associated with decreased dose of warfarin.,C,
1449164032,rs11168292,VDR,warfarin,29298995,Dosage,yes,"This SNP is in very tight linkage disequilibrium with rs11168293 and rs4760658 (r2>0.97). Mean dose (in mg) of warfarin according to genotype was: GG>CG>CC. p-value adjusted for CYP2C9 metabolizer status and VKORC1 activity status phenotypes, among other factors. Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation.",Genotype GG is associated with increased dose of warfarin as compared to genotypes CC + CG.,GG,
1449164073,rs2501873,NR1I3,warfarin,29298995,Dosage,no,Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation.,Allele C is not associated with dose of warfarin as compared to allele T.,C,
1449164097,rs4841588,GATA4,warfarin,29298995,Dosage,no,Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation.,Allele G is not associated with dose of warfarin as compared to allele T.,G,
1449164085,rs2472682,NR1I2,warfarin,29298995,Dosage,no,Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation.,Allele C is not associated with dose of warfarin as compared to allele A.,C,
1451294020,rs1800139,LRP1,warfarin,33094665,Dosage,yes,"For LRP1 rs1800139 (the major allele is T-allele and the minor allele is C-allele), patients carrying TT genotype had a higher demand of WSD (3.10 ± 0.78 mg/day) than those with C-alleles (2.69 ± 0.73 mg/day; adjusted p = 0.045. Patients selected were all ""CYP2C9*1/*1 and VKORC1 -1639 AA genotypes""",Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.,TT,
1451294060,rs1800154,LRP1,warfarin,33094665,Dosage,yes,"The mean daily WSD for those subjects carrying the T-allele of LRP1 rs1800154 (2.70 ± 0.74 mg/day) was significantly lower than that for subjects carrying CC genotype (3.05 ± 0.76 mg/day; raw p = 0.005). The major allele of rs1800154 is C-allele and the minor allele is T-allele. ""After Bonferroni correction, only rs1800139 reached adjusted p-value of less than 0.05"" Patients selected were all ""CYP2C9*1/*1 and VKORC1 -1639 AA genotypes""",Genotype CC is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.,CC,
982047396,CYP2C9*1,CYP2C9,warfarin,22010099,"Dosage,""Metabolism/PK""",yes,,CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*3.,*1/*1,Pediatric
982047450,rs9934438,VKORC1,warfarin,21273734,Dosage,yes,,Genotype AA is associated with decreased dose of warfarin in children with Heart Diseases as compared to genotypes AG + GG.,AA,Pediatric
1449262882,rs1799853,CYP2C9,warfarin,29568565,Dosage,no,"Although in the first analysis, the T allele was not found to be associated with warfarin dose in this population, the polymorphism was included in the International Warfarin Pharmacogenetic Consortium (IWPC), which was compared to a traditional clinical algorithm and the IWPC algorithm predicted dose better than the clinical algorithm.",Allele T is associated with dose of warfarin in people with Cardiovascular Diseases as compared to allele C.,T,
1451130680,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,31653973,Dosage,yes,,CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1.,*2 + *3,
1451130683,rs9934438,VKORC1,warfarin,31653973,Dosage,yes,,Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1451294680,"CYP2C9*1, CYP2C9*3, CYP2C9*13, CYP2C9*16, CYP2C9*60",CYP2C9,warfarin,32893731,Dosage,yes,"The mean stable dose of the CYP2C9*1/*1 group was 3.47 (±1.13) mg/day, which was significantly higher than that of the CYP2C9*1/*3 group (2.30 ± 0.88 mg/day) (p < 0.001). There was only one case of CYP2C9*1/*2 with a dose of 2.50 mg/day and another one case of CYP2C9*3/*3 with a dose of 0.50 mg/day. In regard to other rare CYP2C9 genotypes, there were two cases of CYP2C9*1/*13 with a mean dose of 1.88 mg/day, one case of CYP2C9*1/*16 with a dose of 1.39 mg/day and two cases of CYP2C9*1/*60 with a mean dose of 1.00 mg/d; all of these doses were lower than the mean dose of CYP2C9*1/*1 and CYP2C9*1/*3. The mean dose in carriers with the three rare genotypes, CYP2C9*1/*13, *16 and *60, was 1.42 (±0.54) mg/day which was significantly lower than that of CYP2C9*1/*1 (p < 0.001) and CYP2C9*1/*3 (p < 0.05).",CYP2C9 *1/*13 + *1/*16 + *1/*60 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1 + *1/*3.,*1/*13 + *1/*16 + *1/*60,
655388494,rs1057910,CYP2C9,warfarin,11127854,Dosage,yes,could only access abstract.,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1449246724,rs1043550,CALU,warfarin,28049362,Dosage,no,,Allele G is not associated with dose of warfarin as compared to allele A.,G,
1448276503,"CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,26710337,Dosage,not stated,"This study assessed whether a pharmacogenetic algorithm, which included these variants as well as the VKORC1 rs9923231 and CYP4F2*3 variants, is superior in overall anticoagulation control when compared to clinical standard of care.",CYP2C9 *2 + *3 are associated with dose of warfarin.,*2 + *3,
1449246811,rs12714145,GGCX,warfarin,28049362,Dosage,no,,Allele T is not associated with dose of warfarin as compared to allele C.,T,
1448276458,rs2108622,CYP4F2,warfarin,21725053,Dosage,not stated,"This variant was included in an algorithm generated within this study, the WRAPID Dosing Algorithm.",Allele T is associated with dose of warfarin.,T,
1448276453,rs9923231,VKORC1,warfarin,21725053,Dosage,not stated,"This variant was included in an algorithm generated within this study, the WRAPID Dosing Algorithm.",Allele A is associated with dose of warfarin.,A,
1183699114,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,19177029,Dosage,yes,"Mean stable dose for *1/*3 patients was 1.72 +/- 0.55 mg/day. For *1/*1 patients, the mean stable dose was 3.09 +/- 1.14 mg/day. There was one *3/*3 patient, whose maintenance dose was 0.625 mg/day.",CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3,
1448636895,rs12772169,,warfarin,28686080,Dosage,yes,"in patients initiating warfarin treatment with a target international normalized ratio (INR) of 2 to 3. Direction of the relationship of allele to dose is not explicitly stated. Table 4 lists minor allele as A, dbSNP lists as C/T with T as minor allele.",Allele T is associated with dose of warfarin as compared to allele C.,T,
827823825,rs1057910,CYP2C9,warfarin,21110192,Dosage,yes,C = CYP2C9*3. A = CYP2C9*1. *2 and *3 were pooled together in this comparison to *1. CYP2C9(*2 + *3) were associated with a lower maintenance dose (2.9 vs 3.7 mg for *1). [stat_test:linear regression],Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
827823816,rs1799853,CYP2C9,warfarin,21110192,Dosage,yes,T = CYP2C9*2. C = CYP2C9*1. *2 and *3 were pooled together in this comparison to *1. CYP2C9(*2 + *3) were associated with a lower maintenance dose (2.9 vs 3.7 mg for *1). [stat_test:linear regression],Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1448604092,rs1800566,NQO1,warfarin,28210634,Efficacy,not stated,Case study of one woman who developed deep abdominal vein thrombosis secondary to the use of contraceptives.,Allele A is associated with decreased response to warfarin in women with Thrombosis as compared to allele G.,A,
827823796,rs9923231,VKORC1,warfarin,21110192,Dosage,yes,"The mean dose for CC was higher than CT , which was higher than TT. 4.9 vs. 3.7 vs. 3.1 mg. [stat_test:linear regression]",Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.,CC,
1448276340,rs9923231,VKORC1,warfarin,18183038,Dosage,not stated,This study undertook warfarin prescribing based on CYP2C9*3 and VKORC1 rs9923231 genotype.,Allele A is associated with dose of warfarin.,A,
1183699129,rs1057910,CYP2C9,warfarin,19177029,Dosage,yes,"Mean stable dose for AC (*1/*3) patients was 1.72 +/- 0.55 mg/day. For AA (*1/*1) patients, the mean stable dose was 3.09 +/- 1.14 mg/day. There was one CC (*3/*3) patient, whose maintenance dose was 0.625 mg/day.",Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.,AC,
1448276332,CYP2C9*3,CYP2C9,warfarin,18183038,Dosage,not stated,This study undertook warfarin prescribing based on CYP2C9*3 and VKORC1 rs9923231 genotype.,CYP2C9 *3 is associated with dose of warfarin.,*3,
1449165062,rs9923231,VKORC1,warfarin,28382498,Metabolism/PK,no,"Here, exposure refers to volume of distribution.",Allele T is not associated with exposure to warfarin as compared to allele C.,T,
982047993,rs2108622,CYP4F2,warfarin,22130800,Metabolism/PK,no,,Genotype CC is not associated with dose of warfarin in children as compared to genotype TT.,CC,Pediatric
1449165069,rs9923231,VKORC1,warfarin,28382498,Metabolism/PK,no,Please note: alleles have been complemented to the + chromosomal strand.,Allele T is not associated with clearance of warfarin as compared to allele C.,T,
1448276279,rs9934438,VKORC1,warfarin,25989350,Dosage,not stated,This study assessed the clinical application of genotype-guided dosing of warfarin. The algorithm used to guide dose of warfarin included this variant.,Allele A are associated with dose of warfarin in people with Stroke.,A,
1451340124,rs8050894,VKORC1,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, this variant is associated with 11.7mg/week less warfarin dose requirement compared to wild-type homozygotes.",Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.,CG + GG,
1451340130,rs12777823,,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, this variant is associated with 12.7mg/week less warfarin dose requirement compared to wild-type homozygotes.",Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1451340084,rs2359612,VKORC1,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, this variant is associated with 17.3mg/week less warfarin dose requirement compared to wild-type homozygotes.",Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1451340080,rs9934438,VKORC1,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, this variant is associated with 21.6mg/week less warfarin dose requirement compared to wild-type homozygotes.",Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1447952633,rs12777823,,warfarin,26877068,Dosage,yes,"in African americans, but not European americans.",Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1447952609,rs2108622,CYP4F2,warfarin,26877068,Dosage,yes,"in European americans, but not African americans.",Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
608431827,rs10871454,STX4,warfarin,18535201,Dosage,yes,This SNP accounted for ~25% of the variance in stabilized warfarin dose in a GWAS study. It was in perfect linkage disequilibrium (r2=1) with rs9923231 (VKORC1:-1639),Allele T is associated with decreased dose of warfarin.,T,
608431797,rs339097,CALU,warfarin,20200517,Dosage,yes,,Allele G is associated with increased dose of warfarin.,G,
608431789,rs28371685,CYP2C9,warfarin,20072124,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1451340144,rs7294,VKORC1,warfarin,31869433,Dosage,yes,"In this meta-analysis of warfarin Dose in Black-African Patients, this variant is associated with 6.9mg/week more warfarin dose requirement compared to wild-type homozygotes.",Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
608431793,rs28371686,CYP2C9,warfarin,20072124,Dosage,yes,,Allele G is associated with decreased dose of warfarin as compared to allele C.,G,
827661232,rs9934438,VKORC1,warfarin,16432637,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
608431766,rs2260863,EPHX1,warfarin,19794411,Dosage,no,,Allele G is not associated with dose of warfarin.,G,
608431768,rs1131873,EPHX1,warfarin,19794411,Dosage,yes,,Allele A is associated with decreased dose of warfarin.,A,
608431758,rs1799853,CYP2C9,warfarin,19794411,Dosage,yes,,Allele T is associated with decreased dose of warfarin.,T,
608431781,rs7900194,CYP2C9,warfarin,20072124,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
608431774,rs9923231,VKORC1,warfarin,19794411,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
608431772,rs4653436,EPHX1,warfarin,19794411,Dosage,no,,Allele G is not associated with dose of warfarin.,G,
608431778,rs216013,CACNA1C,warfarin,18535201,Dosage,no,"This intronic variant in the membrane calcium-channel gene CACNA1C was correlated with warfarin dose (p = 9.2 × 10-5) in the index population (n = 181) from a GWAS study of white patients undergoing anticoagulation therapy. Combined analysis of the index and replication populations (n = 374) yielded a p value of 8.6 × 10-7. ""However, this variant did not reach established significance threshold independently in the replication population (P = .002), nor did it achieve significance after multiple testing correction in multivariate modeling (uncorrected P = .003)"".",Allele A is not associated with dose of warfarin.,A,
608431738,rs11653,"CALU,""OPN1SW""",warfarin,19794411,Dosage,no,,Allele T is not associated with dose of warfarin.,T,
608431730,rs1051740,EPHX1,warfarin,19794411,Dosage,no,,Allele C is not associated with dose of warfarin.,C,
608431751,rs2108622,CYP4F2,warfarin,19794411,Dosage,no,"A weak association was found but it did not reach significance: ""In addition, a relationship was found between the CYP4F2 (rs2108622) genotype and warfarin maintenance dose, but it was much weaker than those described earlier. Patients with the wild-type CYP4F2 (rs2108622) sequence (CC) required a mean dose of 2.8 ± 1.5 mg, whereas heterozygotes (CT) and homozygotes (TT) were found to require higher doses (3.0 ± 1.5 mg (+7%) and 3.3 ± 1.7 mg (+18%), respectively; P = 0.13).""",Allele C is associated with dose of warfarin.,C,
608431749,rs2069919,PROC,warfarin,19794411,Dosage,no,,Allele G is not associated with dose of warfarin.,G,
608431743,rs1687390,"ORM1,""ORM2""",warfarin,19794411,,no,,Allele G is not associated with dose of warfarin.,G,
1448624188,rs887829,UGT1A1,warfarin,28550460,Dosage,no,,"Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.",C,
1448624178,rs2108622,CYP4F2,warfarin,28550460,Dosage,yes,,"Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.",TT,
1448624168,rs1057910,CYP2C9,warfarin,28550460,Dosage,yes,,"Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",AC + CC,
1448624157,rs9923231,VKORC1,warfarin,28550460,Dosage,yes,Please note: alleles have been complemented to the + strand.,"Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.",CT + TT,
699638607,rs2108622,CYP4F2,warfarin,18250228,Dosage,yes,4% to 12% increase in the warfarin dose per T allele. This is in Whites presumably of European descent.,Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.,CC,
1185235722,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,24601977,Dosage,yes,Patients who carried the CYP2C9 *2 or *3 variant alleles required 71% the dose of warfarin as compared to those with the wild-type genotype. CYP2C9 genotype was found to account for 6% of the variability in stable warfarin dose (mg/day).,CYP2C9 *1/*2 + *1/*3 + *2/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3 + *2/*3,Pediatric
1185235716,rs9923231,VKORC1,warfarin,24601977,Dosage,yes,Patients with the TT genotype required 48% the dose of those with the CC genotype. VKORC1 genotype was found to account for 13% of the variability in stable warfarin dose (mg/day). Please note that alleles have been complemented to the plus chromosomal strand.,Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CC.,TT,Pediatric
1185235744,rs2108622,CYP4F2,warfarin,24601977,Dosage,no,CYP4F2 genotype was not associated with stable warfarin dose.,Allele C is not associated with dose of warfarin in children as compared to allele T.,C,Pediatric
1185235783,rs12777823,,warfarin,25461246,Dosage,yes,"Observed dose (mg/kg): GG (n=157) 8 (5.0–8.6), GA (n=97) 5.7 (4.3–7.5), AA (n=20) 5.2 (4.3–7.3) p=0.0047",Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
827808098,rs17886199,"PRSS53,""VKORC1""",warfarin,20716240,Dosage,yes,independent of the VKORC1 1173C>T and CYP2C9*2 and *3 variants in African Americans.,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
982046752,rs9923231,VKORC1,warfarin,22010099,Dosage,yes,"Additionally, in a regression model VKORC1 was found to account for 26.6% of the variability observed.",Genotype CC is associated with increased dose of warfarin in children as compared to genotypes CT + TT.,CC,Pediatric
1449260063,rs9934438,VKORC1,warfarin,27617219,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1445117476,"CYP2C9*1, CYP2C9*59",CYP2C9,warfarin,25994031,Dosage,not stated,The patient only required half of the oral amount of warfarin that is commonly used for most Chinese individuals.,CYP2C9 *1/*59 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*59,
1450980580,rs2884737,VKORC1,warfarin,18322281,Dosage,yes,"With *1/*2 (AC) requiring intermediate dose. This was most marked at day 28 to end of follow-up with average doses of 3.66mg/day for *2*2 (HaplotypeA/HaplotypeA""), 4.45mg/day for HaplotypeA/nonA and 5.68mg/day for nonA/nonA. Authors also used rs9923231, rs9934438, rs8050894, and rs2359612 to define HaplotypeA.",Genotype CC is associated with decreased dose of warfarin as compared to genotype AA.,CC,
1450980540,rs9923231,VKORC1,warfarin,18322281,Dosage,yes,"With *1/*2 (CT) requiring intermediate dose. This was most marked at day 28 to end of follow-up with average doses of 3.66mg/day for *2*2 (HaplotypeA/HaplotypeA""), 4.45mg/day for HaplotypeA/nonA and 5.68mg/day for nonA/nonA. Authors also used rs2884737, rs9934438, rs8050894, and rs2359612 to define HaplotypeA.",Genotype TT is associated with decreased dose of warfarin as compared to genotype CC.,TT,
1450980620,rs9934438,VKORC1,warfarin,18322281,Dosage,yes,"With *1/*2 (AG) requiring intermediate dose. This was most marked at day 28 to end of follow-up with average doses of 3.66mg/day for *2*2 (HaplotypeA/HaplotypeA""), 4.45mg/day for HaplotypeA/nonA and 5.68mg/day for nonA/nonA. Authors also used rs9923231, rs2884737, rs8050894, and rs2359612 to define HaplotypeA.",Genotype AA is associated with decreased dose of warfarin as compared to genotype GG.,AA,
1450980643,rs8050894,VKORC1,warfarin,18322281,Dosage,yes,"With *1/*2 (CG) requiring intermediate dose. This was most marked at day 28 to end of follow-up with average doses of 3.66mg/day for *2*2 (HaplotypeA/HaplotypeA""), 4.45mg/day for HaplotypeA/nonA and 5.68mg/day for nonA/nonA. Authors also used rs9923231, rs2884737, rs9934438 , and rs2359612 to define HaplotypeA.",Genotype GG is associated with decreased dose of warfarin as compared to genotype CC.,GG,
981489956,rs2108622,CYP4F2,warfarin,21084764,"Dosage,""Efficacy""",yes,"CC: 3.0 mg/day vs. (CT + TT) : 3.75 mg/day. When the patients were divided into low- and high- dose-requiring subsets based on VKORC1 diplotypes, this association was significant in the low-dose group but not in the high dose group. 18 patients were also taking simvastatin and 19 were also taking omeprazole.",Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.,CC,
1184482805,rs3814637,CYP2C19,warfarin,23941071,Dosage,yes,"The mean warfarin dose in patients with the CYP2C19 rs3814637CC genotype was 3.39mg/day, which was higher than that in patients with the CYP2C19 rs3814637TT genotype (2.00mg/day).",Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.,CC,
1184482810,rs1057910,CYP2C9,warfarin,23941071,Dosage,yes,"The mean warfarin dose in patients with the CYP2C9 rs1057910AA genotype was 3.34 mg/day, which was higher than that in patients with the CYP2C9 rs1057910CC genotype (0.81 mg/day).",Genotypes AA + AC is associated with increased dose of warfarin as compared to genotype CC.,AA + AC,
1184482814,rs699664,GGCX,warfarin,23941071,Dosage,yes,"The mean warfarin dose in patients with the GGCX rs699664 TT genotype was 3.51mg/day, which was higher than that in patients with the GGCX rs699664 CC genotype (3.09 mg/day).",Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
827826043,rs9923231,VKORC1,warfarin,21747589,"Dosage,""Metabolism/PK""",not stated,in Indian patients.,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1184482762,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,23949431,Dosage,yes,in Han-Chinese patients with mechanical heart valve replacement.,CYP2C9 *3/*3 + *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3/*3 + *1/*3,
1184482772,rs2108622,CYP4F2,warfarin,23949431,Dosage,yes,in Han-Chinese patients with mechanical heart valve replacement.,Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
1184482780,rs1057868,POR,warfarin,23949431,Dosage,no,in Han-Chinese patients with mechanical heart valve replacement.,Genotypes CT + TT is not associated with dose of warfarin as compared to genotype CC.,CT + TT,
1184482784,rs2868177,POR,warfarin,23949431,Dosage,no,in Han-Chinese patients with mechanical heart valve replacement.,Genotypes AG + GG is not associated with dose of warfarin as compared to genotype AA.,AG + GG,
1184482790,"CYP2C9*1, CYP2C9*58",CYP2C9,warfarin,25075423,Dosage,not stated,"This variant was detected in a warfarin-hypersensitive patient with the maintenance dose of warfarin was 1.286 mg/day, 36% lower than normal dosing for han-chinese population. The enzymatic activity of the novel allelic variant has been greatly reduced.",CYP2C9 *58 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*58,
1449260681,rs9923231,VKORC1,warfarin,27617219,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1447148309,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,17955230,Dosage,yes,"Patients with the CYP2C9*2 allele (CYP2C9*1*2 or *2*2 genotype) showed no significant difference in the mean dose (5.2±2.4 mg) when compared to CYP2C9*1*1 patients (5.3±2.1 mg), whereas those with at least one copy of the CYP2C9*3 allele (CYP2C9*1*3, *2*3 ,or *3*3 genotype) required a daily dose of 3.1±1.8 mg, corresponding to a 37% reduction, on average, of the standard warfarin dose.",CYP2C9 *1/*3 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3 + *2/*3 + *3/*3,
1447148324,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,17955230,Dosage,no,"Patients with the CYP2C9*2 allele (CYP2C9*1*2 or *2*2 genotype) showed no significant difference in the mean dose (5.2±2.4 mg) when compared to CYP2C9*1*1 patients (5.3±2.1 mg), whereas those with at least one copy of the CYP2C9*3 allele (CYP2C9*1*3, *2*3 ,or *3*3 genotype) required a daily dose of 3.1±1.8 mg, corresponding to a 37% reduction, on average, of the standard warfarin dose.",CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *2/*2,
1447983837,rs2108622,CYP4F2,warfarin,27073641,Dosage,yes,"22 studies with 4,549 were included in the meta-analysis. Most studies were in Chinese patients but 5 were not (2 Japanese, 1 Korean, 1 Indian, 1 Turkish) and one was in a non-specific ""Asian"" population. Most individuals were prescribed warfarin for heart valve replacement, AF, DVT, pulmonary embolism and stroke.",Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1444936324,rs699664,GGCX,warfarin,26106580,Dosage,no,This meta-analysis in Chinese patients showed no difference in mean daily warfarin dose (MDWD) for various genotypes of GGCX variant rs699664.,Allele T is not associated with dose of warfarin as compared to genotype CC.,T,
1445296694,rs2108622,CYP4F2,warfarin,26024874,Dosage,yes,"only in European Americans, but not African Americans. The dose increase per variant allele was higher among European Americans (5.89% vs 1.23%) compared with African Americans.",Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
1184483284,"CYP2C9*1, CYP2C9*12",CYP2C9,warfarin,23688605,Dosage,not stated,,CYP2C9 *1/*12 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*12,
1445296716,rs12777823,,warfarin,26024874,Dosage,yes,"only in African Americans, but not European Americans. However, the dose reduction per variant allele was higher among European Americans (2.3% vs 12.3%, interaction P value=0.006) compared with African Americans.",Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1445296737,"CYP2C9*1, CYP2C9*5, CYP2C9*6, CYP2C9*11",CYP2C9,warfarin,26024874,Dosage,yes,in African Americans.,CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*5 + *6 + *11,
1184483457,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,23208322,Dosage,yes,This variant is evaluated along with VKORC1 rs7294 and ORM1 rs17650.,CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*3,
1445296652,rs9923231,VKORC1,warfarin,26024874,Dosage,yes,"in both European Americans and African Americans. However, the dose reduction per variant allele was higher among European Americans (28.3% vs 18.6%, interaction P value=0.002) compared with African Americans.",Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1183697100,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,22349464,Dosage,yes,"This study endeavored to make a pharmacogenetic algorithm for warfarin dosing. This included two groups, a derivation group and a validation group. In the derivation group, subjects carrying one or two CYP2C9 variant alleles (*2 or *3) showed significantly decreased dose requirements for warfarin treatment as compared to patients with the wildtype genotype (*1/*1). This association was not statistically significant in the validation group. The algorithm used was: Square root of daily dose (mg) = 0.833 - 0.255 (0 for female, 1 for male gender) - 0.007 (age, years) + 0.011 (height, cm) + 0.005 (weight, kg) + 0.385 (smoking, 0=no, 1=yes) + 0.211 (vegetable intake, 0=no, 1=yes) + 0.119 (indication for OAT=VTE, 0=no, 1=yes) + 0.328 (diabetes, 0=no, 1=yes) - 0.458 (variant alleles of CYP2C9, 0, 1, or 2) - 0.571 (VKORC1 -1639 G>A, GG=0, GA=1, AA=2) + 0.025 (VKORC1 3730 G>A, GG=0, GA=1, AA=2). This algorithm underperformed most other published algorithms when determining dose for patients needing doses lower than 44 mg/week, but outperformed all other algorithms when determining dose for patients needing doses greater than or equal to 45 mg/week.",CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*2 + *3,
827661941,rs1057910,CYP2C9,warfarin,16432637,"Dosage,""Metabolism/PK""",yes,,Genotypes AC + CC are associated with decreased dose of warfarin as compared to genotype AA.,AC + CC,
1448573256,"CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8, CYP2C9*11",CYP2C9,warfarin,28135054,Dosage,yes,"in African American patients. CYP2C9 star alleles were grouped together for analysis ( CYP2C9*2, *3, *5, *8, *11).",CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *3 + *5 + *8 + *11,
1448573250,rs9923231,VKORC1,warfarin,28135054,Dosage,yes,in African American patients.,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1449577166,CYP2C9*3,CYP2C9,warfarin,29986700,Dosage,not stated,used in a study comparing genotype-guided dosing vs conventional for warfarin initiation.,"CYP2C9 *3 is associated with dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism, Stroke and Venous Thrombosis.",*3,
1449577192,CYP2C9*3,CYP2C9,warfarin,17015052,Dosage,not stated,as part of a model estimating mean daily warfarin requirements in milligrams per day.,CYP2C9 *3 is associated with dose of warfarin.,*3,
827647045,rs9934438,VKORC1,warfarin,16611750,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
827925134,rs2108622,CYP4F2,warfarin,22528326,Dosage,yes,,Genotypes CT + TT are associated with increased dose of warfarin in people with Thromboembolism as compared to genotype CC.,CT + TT,
1184169096,rs1057910,CYP2C9,warfarin,24728385,Dosage,yes,"The goal of this study was to compare the accuracy of 8 different warfarin dosing algorithms, including the IWPC, and 6 Han Chinese PGx warfarin dosing algorithms, in Han Chinese patients taking warfarin scheduled to undergo mechanic heart valve replacement surgery. The authors concluded that the mean absolute error (MAE) of all algorithms was less than 0.6mg/day in initial and stable doses, and the percentage of patients whose actual doses were within 20% of their predicted dose was 45% for all algorithms. Predictive power of algorithms was highest for patients in the ideal-dose range and lowest for patients in the low and high dose range. The most accurate predictions came from three Han-Chinese PGx warfarin dosing algorithms (Du et al. 2010, Huang et al. 2009, Miao et al. 2007).",Genotype AA is associated with increased dose of warfarin in people with Heart Valve Diseases as compared to genotype AC.,AA,
982036689,rs1799853,CYP2C9,warfarin,18542936,Dosage,yes,"in Turkish patients taking warfarin for >2 months. This variant defines CYP2C9*2. Homozygous variant genotype (*2/*2,*2/*3,and *3/*3) are grouped together, and heterozygous variant genotype (*1/*2,*1/*3,and *1/*4) are grouped together for analysis. Patients carrying one or two copies of CYP2C9 variant alleles are associated with lower dose of warfarin as compared to the homozygous wild type patients.",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
982036710,rs56165452,CYP2C9,warfarin,18542936,Dosage,yes,"in Turkish patients taking warfarin for >2 months. This variant defines CYP2C9*4. Homozygous variant genotype (*2/*2,*2/*3,and *3/*3) are grouped together, and heterozygous variant genotype (*1/*2,*1/*3,and *1/*4) are grouped together for analysis. Patients carrying one or two copies of CYP2C9 variant alleles are associated with lower dose of warfarin as compared to the homozygous wild type patients.",Allele C is associated with decreased dose of warfarin as compared to allele T.,C,
982036670,rs9923231,VKORC1,warfarin,18542936,Dosage,yes,in Turkish patients taking warfarin for >2 months.,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
827664180,rs9923231,VKORC1,warfarin,16580898,Dosage,yes,,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1184513812,rs2592551,GGCX,warfarin,24148610,Dosage,yes,Please note alleles have been complemented to the plus chromosomal strand.,Genotypes AA + AG is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotype GG.,AA + AG,
1449250920,rs699664,GGCX,warfarin,28049362,Dosage,no,,Allele T is not associated with dose of warfarin as compared to allele C.,T,
1449005162,rs1057910,CYP2C9,warfarin,29054760,Dosage,yes,,Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.,AC,
1449005156,rs9934438,VKORC1,warfarin,29054760,Dosage,yes,,Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
1449005167,rs2108622,CYP4F2,warfarin,29054760,Dosage,yes,,Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.,TT,
1449005177,rs10950022,VKORC1L1,warfarin,29054760,"Dosage,""Metabolism/PK""",no,,Genotypes CC + CT is associated with decreased dose of warfarin as compared to genotype TT.,CC + CT,
1449005185,rs4072879,VKORC1L1,warfarin,29054760,Dosage,yes,,Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
1449005190,rs1877724,EPHX1,warfarin,29054760,Dosage,no,,Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.,CC,
1449005213,rs1057910,CYP2C9,warfarin,28262345,Dosage,yes,,Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.,AC,
1449005203,rs9934438,VKORC1,warfarin,28262345,Dosage,yes,,Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
1449005223,rs7975232,VDR,warfarin,28262345,Dosage,no,"This variant alone is not significantly associated with warfarin dose. However, ""patients with the genotype combination GT,TT/CT,CC of VDR rs7975232/rs2228570 required significantly higher stable warfarin dose (5.79±2.02mg) than those with the other genotypic combinations (5.19±1.78mg, p=0.034). Multivariate analysis showed that VDR rs7975232/rs2228570 explained 2.0% of the 47.5% variability in overall warfarin dose.""",Genotype CC is not associated with decreased dose of warfarin as compared to genotypes AA + AC.,CC,
1449005229,rs2228570,VDR,warfarin,28262345,Dosage,no,"This variant alone is not significantly associated with warfarin dose. However, ""patients with the genotype combination GT,TT/CT,CC of VDR rs7975232/rs2228570 required significantly higher stable warfarin dose (5.79±2.02mg) than those with the other genotypic combinations (5.19±1.78mg, p=0.034). Multivariate analysis showed that VDR rs7975232/rs2228570 explained 2.0% of the 47.5% variability in overall warfarin dose.""",Genotype AA is not associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
1449005291,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,28689179,Dosage,yes,"CYP2C9 and VKORC1 variants are analyzed together to divide patients into three warfarin sensitivity types (normal, sensitive and highly sensitive). ""Warfarin sensitive and highly sensitive responders had heparin therapy discontinued earlier (p<0.001), had a decreased final weekly warfarin dose (p<0.001), spent more time over-anticoagulated (p<0.001) and had an increased bleeding risk with warfarin (sensitive responders HR 1.38 [95% CI 1.11 to 1.71], p=0.0035; highly sensitive responders 1.79 [1.09 to 2.99]; p=0.0252).""",CYP2C9 *2 + *3 are associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.,*2 + *3,
1184510322,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,21320153,Dosage,yes,in a Southern Brazilian population of European ancestry.,CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3 + *2/*2 + *2/*3,
1448268060,rs9934438,VKORC1,warfarin,22534826,Dosage,yes,"Patients with the AG or GG genotypes received significantly higher doses of warfarin as compared to those with the AA genotype (3.12+/-1.20 mg/day vs 2.36+/-0.87 mg/day). Additionally, this study developed a pharmacogenetic algorithm to predict daily stable dose of warfarin in Chinese patients; this variant was present in the algorithm. This variant was in complete linkage with rs9923231 (VKORC1 -1639 C>T). Please note that alleles have been complemented to the plus chromosomal strand.",Genotypes AG + GG are associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA.,AG + GG,
1184510339,rs9923231,VKORC1,warfarin,21320153,Dosage,yes,in a Southern Brazilian population of European ancestry.,Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1448268037,rs2108622,CYP4F2,warfarin,22534826,Dosage,yes,"Patients with the TT genotype had a higher mean warfarin daily dose requirement (3.04+/-0.98 mg/day) as compared to those with the CT (2.66+/-1.02 mg/day, p=0.037) or CC (2.60+/-0.84 mg/day, p=0.034). Additionally, this study developed a pharmacogenetic algorithm to predict daily stable dose of warfarin in Chinese patients; this variant was present in the algorithm.",Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotypes CC + CT.,TT,
1448268043,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,22534826,Dosage,yes,"The mean warfarin daily dose required was significantly lower in patients with the *1/*3 genotype (1.93+/-1.14 mg/day) as compared to those with the *1/*1 genotype (2.72+/-0.89 mg/day). Additionally, this study developed a pharmacogenetic algorithm to predict daily stable dose of warfarin in Chinese patients; this variant was present in the algorithm.",CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.,*1/*3,
1184756122,rs4917639,CYP2C9,warfarin,25126975,Dosage,yes,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model."" rs4917639 only remained significantly associated with warfarin maintenance dose in the first cohort but did not remain significant in the multivariate analysis.",Allele C is associated with decreased dose of warfarin in people with heart valve replacement as compared to allele A.,C,
1184510263,"CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*11",CYP2C9,warfarin,21590310,Dosage,yes,,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *6 + *5 + *11,
1184510278,"CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9, CYP2C9*11",CYP2C9,warfarin,21590310,Dosage,yes,,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.,*2 + *6 + *5 + *11,
1448267942,rs9934438,VKORC1,warfarin,26996562,Dosage,not stated,"Warfarin dose was 6 mg/day in the one patient with the GG genotype, and 4.6+/-1.9 mg/day in the 17 patients with the AG genotype, as compared to 3.6+/-1.2 in patients with the AA genotype. Additionally, this study undertook the development of a warfarin pharmacogenetic dosing algorithm and then compared it against other dosing algorithms. This variant was included in the algorithm. Please note that alleles have been complemented to the plus chromosomal strand.",Genotypes AG + GG are associated with increased dose of warfarin in people with Stroke as compared to genotype AA.,AG + GG,
1448267909,rs9934438,VKORC1,warfarin,20585834,Dosage,yes,"The mean stable doses of patients with the GG genotype (6.63+/-1.61 mg/day) and AG genotype (4.41+/-1.45 mg/day) were significantly higher than patients with the AA genotype (2.92+/-1.01 mg/day). The study also generated a warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. This variant was included in the algorithm. Please note that alleles have been complemented to the plus chromosomal strand.",Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.,AG + GG,
1448267915,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,20585834,Dosage,yes,"The study generated a warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. This variant was significantly associated with stable warfarin dose in stepwise multivariate analysis, and was included in the algorithm.",CYP2C9 *1/*3 is associated with dose of warfarin.,*1/*3,
1448267884,rs9923231,VKORC1,warfarin,20339191,Dosage,yes,The study evaluated the International Warfarin Pharmacogenetics Consortium (IWPC) algorithm against a clinical algorithm for warfarin dose requirements in Japanese patients. This variant was included in the IWPC algorithm. Please note that alleles have been complemented to the plus chromosomal strand.,Genotypes CT + TT are associated with dose of warfarin.,CT + TT,
1448267890,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,20339191,Dosage,not stated,The study evaluated the International Warfarin Pharmacogenetics Consortium (IWPC) algorithm against a clinical algorithm for warfarin dose requirements in Japanese patients. This variant was included in the IWPC algorithm.,CYP2C9 *1/*3 + *3/*3 are associated with dose of warfarin.,*1/*3 + *3/*3,
827845924,rs72558187,CYP2C9,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose. Described as CYP2C9*13 in this study.,Allele C is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele T.,C,
827845911,rs1045642,ABCB1,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose.,Allele A is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele G.,A,
827845885,rs4986910,CYP3A4,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose. Also described as CYP3A4*3 in this study.,Allele G is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele A.,G,
1184510620,rs12714145,GGCX,warfarin,21195460,Dosage,yes,,Genotype TT is associated with increased dose of warfarin as compared to genotype CC.,TT,
827567352,rs12714145,GGCX,warfarin,15883587,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele T.,C,
827567361,rs9923231,VKORC1,warfarin,15888487,"Dosage,""Metabolism/PK""",yes,,Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.,TT,
827845864,rs12460590,CYP2A6,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose. Also described as CYP2A6*5 in this study.,Allele A is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele C.,A,
1184756280,rs2108622,CYP4F2,warfarin,25126975,Dosage,yes,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model."" rs2108622 was not significantly associated with warfarin maintenance dose in the first cohort but was significant in the multivariate analysis.",Allele C is associated with decreased dose of warfarin in people with heart valve replacement as compared to allele T.,C,
827845844,rs762551,CYP1A2,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose. Alleles A and C were given in the paper (CYP1A2*1F).,Allele A is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele C.,A,
827567329,rs7294,VKORC1,warfarin,15883587,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele T.,C,
827845835,rs2069514,CYP1A2,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose.,Allele A is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele G.,A,
827567313,rs9934438,VKORC1,warfarin,15883587,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
827845820,rs1048943,CYP1A1,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose. Please note that A/G alleles were given (complementary alleles are given here).,Allele C is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele T.,C,
827845815,rs9332127,CYP2C9,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose.,Allele C is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele G.,C,
1448431531,rs4124874,UGT1A1,warfarin,26223945,Dosage,no,Analysis was performed on stable warfarin dose.,Genotype TT is not associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes GG + GT.,TT,
827845798,rs1057910,CYP2C9,warfarin,22248286,Dosage,yes,warfarin-maintenance dose. also referred to as CYP2C9*3 (allele C). No individuals in the cohort had the genotype CYP2C9*3/*3 (CC).,Genotype AC is associated with decreased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to genotype AA.,AC,
1448431525,rs4148323,UGT1A1,warfarin,26223945,Dosage,no,Analysis was performed on stable warfarin dose.,Genotypes AG + GG are not associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.,AG + GG,
1447677865,rs4889606,STX1B,warfarin,26751406,Dosage,yes,"in both European-Americans, and Egyptians. ""However, STX1B rs4889606 was in high linkage disequilibrium with VKORC1-1639 G>A, and was no longer significant after including VKORC1-1639 G>A in the regression model. Based on these data, the polymorphisms do not appear to influence, in a clinically important way, warfarin dose requirements in European-Americans and Egyptians. """,Genotypes AG + GG are associated with decreased dose of warfarin as compared to genotype AA.,AG + GG,
1448431519,rs887829,UGT1A1,warfarin,26223945,Dosage,yes,Analysis was performed on stable warfarin dose.,Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.,CC,
1448431513,rs2108622,CYP4F2,warfarin,26223945,Dosage,yes,Analysis was performed on stable warfarin dose. Alleles give was reverse strand A and G.,Genotypes CC + CT are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype TT.,CC + CT,
1448431507,rs1057910,CYP2C9,warfarin,26223945,Dosage,yes,Analysis was performed on stable warfarin dose.,Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.,AA,
1447677830,rs7856096,FPGS,warfarin,26751406,Dosage,no,"in European-Americans, and Egyptians.",Genotype AA is not associated with dose of warfarin as compared to genotypes AG + GG.,AA,
1448431482,rs9934438,VKORC1,warfarin,26223945,Dosage,yes,Analysis was performed on stable warfarin dose.,Genotypes AG + GG are associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.,AG + GG,
1447677818,rs12714145,GGCX,warfarin,26751406,Dosage,no,"in European-Americans, and Egyptians.",Genotype CC is not associated with dose of warfarin as compared to genotypes CT + TT.,CC,
982034232,rs9934438,VKORC1,warfarin,16270629,Dosage,not stated,This SNP corresponds to VKORC1*2.,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1444695840,"CYP2C9*1, CYP2C9*8",CYP2C9,warfarin,25712185,Metabolism/PK,yes,"in African Americans. Patients with CYP2C9*8 had a 30% reduction in S-warfarin clearance as compared to patients with *1/*1 genotype. CYP2C9*8, but not CYP2C9*2/*3, and body surface area (BSA)/body weight were determinants of S-warfarin clearance (CL[S]) in African–American. Dosing algorithm that excludes African-specific variant(s) may lead to prediction errors in African Americans.",CYP2C9 *1/*8 + *8/*8 are associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.,*1/*8 + *8/*8,
982034243,rs7294,VKORC1,warfarin,16270629,Dosage,not stated,This SNP corresponds to VKORC1*3.,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1448267502,"CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,18662264,Dosage,not stated,"Generation of an algorithm to predict warfarin dose based on these variants as well as VKORC1 rs9923231 and clinical factors, as well as analyses on the performance of the algorithm vs a clinical algorithm.",CYP2C9 *2 + *3 are associated with dose of warfarin.,*2 + *3,
1448267496,rs9923231,VKORC1,warfarin,18662264,Dosage,not stated,"Generation of an algorithm to predict warfarin dose based on this rsID as well as CYP2C9*2 and *3 and clinical factors, as well as analyses on the performance of the algorithm vs a clinical algorithm.",Allele A is associated with dose of warfarin as compared to allele G.,A,
769168957,rs11676382,GGCX,warfarin,20694283,Dosage,yes,This variant was associated with a 6.1% reduction in warfarin dose per G allele.The clinical impact was modest.,Allele G is associated with decreased dose of warfarin as compared to allele C.,G,
1444695597,rs11676382,GGCX,warfarin,25681132,Dosage,yes,"Patients with the G allele (that is, carried the GGCX rs11676382 CG or GG genotypes) required 27% lower warfarin dose than CC genotype.",Genotypes CG + GG is associated with decreased dose of warfarin as compared to genotype CC.,CG + GG,
1448267368,rs10517,NQO1,warfarin,27740732,Dosage,yes,All participants were warfarin-naive.,Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AG + GG.,AA,
1444695604,rs699664,GGCX,warfarin,25681132,Dosage,no,,Genotypes CT + TT is not associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1448267343,rs72800847,STX1B,warfarin,27740732,Dosage,yes,All participants were warfarin-naive.,Genotypes AA + AG is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype GG.,AA + AG,
1448267332,rs3826041,CYP1A1,warfarin,27740732,Dosage,yes,All participants were warfarin-naive.,Genotype CC is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AA + AC.,CC,
1448267319,rs2304429,DNMT3A,warfarin,27740732,Dosage,yes,All participants were warfarin-naive.,Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.,TT,
1184757003,rs2290228,CALU,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,G,
1184757013,rs9332127,CYP2C9,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele C.,G,
1184757023,rs4244285,CYP2C19,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,G,
1184757033,rs339097,CALU,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,G,
1184757028,rs4986893,CYP2C19,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,G,
1450935595,rs9923231,VKORC1,warfarin,31444512,Dosage,yes,in patients early after heart valve replacement surgery.,Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.,TT,
1450935601,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,31444512,Dosage,yes,in patients early after heart valve replacement surgery.,CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3,
1184757043,rs12714145,GGCX,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele C is not associated with dose of warfarin in people with heart valve replacement as compared to allele T.,C,
1184757038,rs699664,GGCX,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele C is not associated with dose of warfarin in people with heart valve replacement as compared to allele T.,C,
1184757050,rs3756009,F11,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,G,
1184757065,rs1415774,PROCR,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,G,
1184757060,rs3136516,F2,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,G,
1184757070,rs12065184,MPZ,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele C is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,C,
981344731,"CYP2C19*1, CYP2C19*2",CYP2C19,warfarin,12496751,"Dosage,""Metabolism/PK""",no,This paper used *1 and *2 to describe the different CYP2C19 haplotypes. No relationship was found between CYP2C19 genotype and clearance of either the S- or R-warfarin enantiomers.,CYP2C19 *2 is not associated with increased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C19 *1.,*2,
1184511620,rs1057910,CYP2C9,warfarin,25026456,Dosage,yes,in Korean patients with prosthetic cardiac valves.,Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.,AC,
1184511624,rs2645400,GATA4,warfarin,25026456,Dosage,yes,"in Korean patients with prosthetic cardiac valves carrying CYP2C9*1/*1 (p=0.026), but not in the CYP2C9 variant group (p=0.122).",Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT.,TT,
1184511628,rs4841588,GATA4,warfarin,25026456,Dosage,yes,"in Korean patients with prosthetic cardiac valves carrying CYP2C9*1/*1 (p=0.036), but not in the CYP2C9 variant group (p=0.114).",Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT.,TT,
1184511552,rs9923231,VKORC1,warfarin,25042728,Dosage,yes,,Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1184511561,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,25042728,Dosage,yes,,CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3,
1184511577,rs2108622,CYP4F2,warfarin,25042728,Dosage,yes,,Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
769250174,rs12782374,CYP2C9,warfarin,19855097,"Dosage,""Metabolism/PK""",no,"after excluding those patients carrying CYP2C9*2, *3, and VKORC1 variant alleles.",Allele A is not associated with dose of warfarin in people with stable INRs in target range of 2-3 as compared to allele G.,A,
769250177,rs71486745,CYP2C9,warfarin,19855097,"Dosage,""Metabolism/PK""",no,"after excluding those patients carrying CYP2C9*2, *3, and VKORC1 variant alleles.",Allele del is not associated with dose of warfarin in people with stable INRs in target range of 2-3 as compared to allele GT.,del,
982033139,rs9923231,VKORC1,warfarin,20833655,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
981345098,CYP2C19*2,CYP2C19,warfarin,12496751,Metabolism/PK,no,This paper used *1 and *2 to describe the different CYP2C19 haplotypes. No relationship was found between CYP2C19 genotype and weekly dosage of warfarin.,CYP2C19 *2 is not associated with decreased dose of warfarin in people with Cardiovascular Diseases.,*2,
1444694702,rs1057910,CYP2C9,warfarin,25594941,Metabolism/PK,no,130 plasma samples were obtained 12 hours after the last dose of warfarin. The plasma warfarin concentrations of these samples were comparing plasma concentration within a group of patients with INR between 1.5–2.5 (n = 92) between genotype groups. The relationship between plasma concentration and maintenance dose was evaluated to explore the effect of rs1057910 (CYP2C9) on the pharmacokinetics of warfarin. Within both the low-dosage group (<17.5 mg/w) and the middle-dosage group (17.5–26.25 mg/w) the AC genotypes required higher plasma concentration as compared to the AA genotypes although the differences were not statistically significant.,Genotype AA is not associated with concentrations of warfarin in people with heart valve replacement as compared to genotype AC.,AA,
1444694721,rs9923231,VKORC1,warfarin,25594941,Dosage,yes,"58/220 patients had the target INR (1.5–2.5). The comparison of weekly warfarin maintenance dose was among patients of different genotypes. The AA genotype of rs9923231 required a significantly lower maintenance dose than the AG genotype (rs9923231: 19.21±5.66 mg/w vs 28.62±8.02 mg/w, p < 0.001; ANOVA). rs9923231 and rs1057910 had significant effects on maintenance dose (rs9923231: coefficient was 1.398, p < 0.001; rs1057910: coefficient was-0.994, p < 0.001) and together explained apx. 32.0% of warfarin maintenance dose variability.",Genotype TT is associated with decreased dose of warfarin in people with as compared to genotype CT.,TT,
982033269,rs1057910,CYP2C9,warfarin,10073515,"Dosage,""Efficacy"",""Toxicity""",not stated,"Reduced function alleles CYP2C9*2 and CYP2C9*3 are pooled together for analysis. ""Patients in the low-dose group were more likely to have difficulties at the time of induction of warfarin therapy (5.97 [2.26-15.82]) and have increased risk of major bleeding complications (rate ratio 3.68 [1.43-9.50]) when compared with randomly selected clinic controls.""",Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1444694638,rs2108622,CYP4F2,warfarin,25594941,Dosage,no,130 plasma samples were obtained 12 hours after the last dose of warfarin. The plasma warfarin concentrations of these samples were comparing plasma concentration within the group of patients with INR between 1.5–2.5 (n = 92). Please note: alleles have been complemented to the + chromosomal strand.,Genotypes CT + TT are not associated with concentrations of warfarin in people with heart valve replacement as compared to genotype CC.,CT + TT,
981754835,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,23061746,Dosage,yes,"Comparison of *1/*1 to (*1/*2, *1/*3) and to (*2/*2, *2/*3 and *3/*3) was significant as was comparison between *1/*1 to (*1/*2, *1/*3) and *1/*1 and (*2/*2, *2/*3 and *3/*3).",CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3.,*1/*1,
1444694650,rs699664,GGCX,warfarin,25594941,Dosage,no,158/220 patients had the target INR (1.5–2.5). The comparison of weekly warfarin maintenance dose was among patients of different genotypes. Differences in maintenance dose were not observed in patients with variant genotypes of GGCX rs699664.,Genotypes CT + TT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype CC.,CT + TT,
1444694656,rs699664,GGCX,warfarin,25594941,Dosage,no,130 plasma samples were obtained 12 hours after the last dose of warfarin. The plasma warfarin concentrations of these samples were comparing plasma concentration within the group of patients with INR between 1.5–2.5 (n = 92) between genotype groups.,Genotypes CT + TT are not associated with concentrations of warfarin in people with heart valve replacement as compared to genotype CC.,CT + TT,
981754851,rs2108622,CYP4F2,warfarin,23061746,Dosage,yes,,Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.,CC,
1444694693,rs1057910,CYP2C9,warfarin,25594941,Dosage,yes,"158/220 patients had the target INR (1.5–2.5). The comparison of weekly warfarin maintenance dose was among patients of different genotypes. The mean maintenance dose per week was significantly lower in the rs1057910 AC genotype (15.31±5.26 mg/w) vs the AA genotype (21.21±6.98 mg/w, p = 0.002 ANOVA). rs9923231 and rs1057910 had significant effects on maintenance dose (rs9923231: coefficient was 1.398, p < 0.001; rs1057910: coefficient was-0.994, p < 0.001) and together explained apx. 32.0% of warfarin maintenance dose variability.",Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.,AA,
1184511945,"CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8",CYP2C9,warfarin,24029542,Metabolism/PK,yes,"Where *1/*2, *1/*3, and *1/*8 are intermediate metabolizers (IM), and *2/*3 and 2/*2 are poor metabolizers (PM). Extensive metabolizers (EM) required a higher median cumulative therapeutic dose of warfarin to reach the target international normalized ratio (INR), as compared to intermediate and poor metabolizers. 54% of the variability in dose was attributable to CYP2C9 genotype. Additionally, subjects who had a PM or IM genotype and the rs9923231 AA or AG genotype required the fewest days to reach target anticoagulation intensity (p=0.01) and the lowest median cumulative therapeutic dose of warfarin to reach the target international normalized ratio (INR) (p=0.007), as compared against patients with the EM + GG, EM + AG and IM/PM (specifically *1/*8 and *2/*3) + GG genotypes.",CYP2C9 *1/*1 (assigned as normal metabolizers phenotype) is associated with increased dose of warfarin in healthy individuals as compared to CYP2C9 *1/*2 + *1/*3 + *1/*8 + *2/*3 + *2/*2 (assigned as poor metabolizers and intermediate metabolizers phenotype) .,*1/*1,
1184511955,rs2108622,CYP4F2,warfarin,24029542,Metabolism/PK,yes,"Those with the CT and TT genotype required a higher median cumulative therapeutic dose of warfarin to reach the target international normalized ratio (INR), as compared to those with the CC genotype. 1% of the variability in dose was attributable to CYP4F2 rs2108622 genotype. Please note alleles have been complemented to the plus chromosomal strand.",Genotypes CT + TT is associated with increased dose of warfarin in healthy individuals as compared to genotype CC.,CT + TT,
981754860,rs1131873,EPHX1,warfarin,23061746,Dosage,no,,Allele G is not associated with decreased dose of warfarin as compared to allele A.,G,
982033561,rs1799853,CYP2C9,warfarin,10961881,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1447680216,rs4645974,MYC,warfarin,26249541,Dosage,yes,This variant was found to be significant in the multivariate analysis and accounted for approximately 2.4% of variability in warfarin dose.,Genotype CC is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.,CC,
1447680201,rs4645962,MYC,warfarin,26249541,Dosage,yes,"There were no CC homozygotes observed. ""Patients with TC alleles of c-Myc rs4645962 required a 30% dose reduction compared with patients carrying TT alleles.""",Genotype CT is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype TT.,CT,
827814765,rs1799853,CYP2C9,"acenocoumarol,""warfarin""",21148049,Dosage,not stated,in Lebanese participants on long-term warfarin or acenocoumarol maintenance therapy irrespective of VKORC1 genotypes. CYP2C9*2 had the least impact on the response to both drugs as compared to CYP2C9*3 and VKORC1 rs9923231.,Allele T is not associated with decreased dose of acenocoumarol or warfarin as compared to allele C.,T,
827814719,rs9923231,VKORC1,warfarin,21148049,Dosage,yes,in Lebanese participants on long-term warfarin therapy.,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
637880249,rs9923231,VKORC1,warfarin,19228618,Dosage,yes,,Allele T is associated with decreased dose of warfarin.,T,
637880237,rs9923231,VKORC1,warfarin,19300499,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
637880256,rs9923231,VKORC1,warfarin,18535201,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
827602050,rs1799853,CYP2C9,warfarin,18305455,Dosage,yes,CYP2C9*2 is associated with a 19% decrement in the warfarin dose per allele.,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1183689399,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,22990331,Dosage,yes,Patients carrying at least one copy of the CYP2C9 *2 or *3 alleles needed significantly lower doses of warfarin and also showed significantly greater variability in dose as compared to patients with the wildtype *1/*1 genotype.,CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*2 + *3,
1448105757,rs61742245,VKORC1,warfarin,17110455,Dosage,yes,"Asp36Tyr was significantly associated with doses of more than 70 mg/wk (odds ratio, 13.0; 95% confidence limit, 1.3 to 124.2).",Allele A is associated with increased dose of warfarin as compared to allele C.,A,
827601694,rs9923231,VKORC1,warfarin,18305455,Dosage,yes,This variant was associated with a 28% reduction per allele (95% confidence interval 25-30%) in the therapeutic warfarin dose.,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
637879838,rs9923231,VKORC1,warfarin,20203262,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
827863717,rs2242480,CYP3A4,warfarin,21692828,"Other,""Metabolism/PK""",not stated,"For R-Warfarin in a model that included bodyweight, age and CYP2C19 rs3814637.",Genotype CT is associated with increased clearance of warfarin as compared to genotype CC.,CT,
827863702,rs3814637,CYP2C19,warfarin,21692828,"Other,""Metabolism/PK""",not stated,"For R-Warfarin in a model that included bodyweight, age and CYP3A4 rs2242480.",Allele T is associated with decreased clearance of warfarin as compared to allele C.,T,
1183690079,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,22855348,Efficacy,yes,"Patients in this study were treated with low dose (1-2mg/day) warfarin. Patients with the *1/*3 genotype showed significantly higher S-warfarin concentrations and higher prothrombin times (INR) as compared to patients with the *1/*1 genotype. When CYP2C9 was analyzed in tandem with VKORC1, it was found that those patients with the highest number of variants (VKORC1 -1639 A alleles and CYP2C9 *3 alleles) had the highest INR measurements as compared to patients wildtype for both genes (-1639 GG VKORC1 genotype and CYP2C9 *1/*1) who had the lowest INR measurements.",CYP2C9 *1/*3 is associated with increased response to warfarin as compared to CYP2C9 *1/*1.,*1/*3,
981481812,rs2108622,CYP4F2,warfarin,20833655,"Dosage,""Efficacy""",yes,"The association was not significant in a GWAS comparing high and low-dose warfarin requirers, but was significant after results were first stratified by rs10509680 (CYP2C9) and rs9923231 (VKORC1) genotypes.",Allele T is associated with increased dose of warfarin as compared to allele C.,T,
981481830,rs2108622,CYP4F2,warfarin,20833655,"Dosage,""Efficacy""",yes,This was a replication cohort. Results were first stratified by rs10509680 (CYP2C9) and rs9923231 (VKORC1) genotypes.,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1183690069,rs9923231,VKORC1,warfarin,22855348,Efficacy,yes,"Patients in this study were treated with low dose (1-2mg/day) warfarin. This SNP was presented as VKORC1 -1639 G>A. Prothrombin time (INR) was significantly different among genotype groups and was observed as follows: AA>AG>GG. When VKORC1 was analyzed in tandem with CYP2C9, it was found that those patients with the highest number of variants (VKORC1 A alleles and CYP2C9 *3 alleles) also had the highest INR measurements as compared to patients wildtype for both genes (GG VKORC1 genotype and CYP2C9 *1/*1) who had the lowest INR measurements.",Genotype TT is associated with increased response to warfarin as compared to genotypes CC + CT.,TT,
1448269030,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,21326313,Dosage,yes,"The mean warfarin dose was higher in patients with the *1/*1 genotype (3.5+/-2.0) as compared to those with the *1/*3 genotype (2.5+/-1.0). Additionally, this variant was included in an algorithm for determining warfarin dose.",CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *1/*3.,*1/*1,
1183690095,CYP2C19 poor metabolizer genotype,CYP2C19,warfarin,22855348,Efficacy,no,"Patients in this study were treated with low dose (1-2mg/day) warfarin. While CYP2C19 genotype was not associated with a clinical outcome from warfarin therapy, those patients classified as poor metabolizers (*2/*2, *2/*3, and *3/*3; no *3/*3 patients were found in this study) showed significantly lower concentrations of S-warfarin and lower S-/R-warfarin ratios as compared to patients classified as intermediate (*1/*2, *1/*3) or extensive metabolizers(*1/*1).",CYP2C19 poor metabolizer genotype is not associated with increased response to warfarin as compared to CYP2C19 normal metabolizer genotype.,,
1448268948,"CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,24251363,Dosage,not stated,Study undertaking a randomized trial of genotype-guided dosing of warfarin. The algorithms that the study used to calculate loading dose and dose revision on day 4 or 5 of treatment included these variants.,CYP2C9 *2 + *3 is associated with dose of warfarin in people with Atrial Fibrillation and venous thromboembolism.,*2 + *3,
981858915,rs9934438,VKORC1,warfarin,23183958,Dosage,yes,"The authors stated ""The full multiple linear regression model revealed that VKORC1 genotypes accounted for 47% of dosing variability. CYPC29 accounted for 5%. Overall, the combination of VKORC1, CYP2C9, age, and target INR accounted for 82% of dosing variability."" in children.",Genotype GG is associated with increased dose of warfarin in children as compared to genotypes AA + AG.,GG,Pediatric
769182565,rs2108622,CYP4F2,warfarin,21383771,Dosage,yes,Patients had a stable therapeutic international normalized ratio (INR) between 2 and 3.,Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
769182559,rs1057910,CYP2C9,warfarin,21383771,Dosage,yes,Patients had a stable therapeutic international normalized ration (INR) between 2 and 3.,Genotype AA is associated with increased dose of warfarin as compared to genotypes AC + CC.,AA,
769182562,rs7196161,VKORC1,warfarin,21383771,Dosage,yes,Patients had a stable therapeutic international normalized ratio (INR) between 2 and 3.,Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.,AA + AG,
981858924,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,23183958,Dosage,no,"The authors state that ""CYPC29 accounted for 5%"" of dosing variability in the full multiple linear regression model. (as compared to VKORC1 which accounted for 47% of dosing variability, and age and target INR which contribute about 30%).",CYP2C9 *1/*2 + *1/*3 is not associated with dose of warfarin in children as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3,Pediatric
827783312,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,22040439,Dosage,no,"In combination with VKORC1 rs9923231 TT. Doses for the 2 cases were 0.625 mg/d for case 1, and 1.25 mg/d for case 2. Target INRs 2-3.",CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.,*3/*3,
827783301,rs9923231,VKORC1,warfarin,22040439,Dosage,no,"In combination with CYP2C9*3*3. Doses for the 2 cases were 0.625 mg/d for case 1, and 1.25 mg/d for case 2. Target INRs 2-3.",Genotype TT is associated with decreased dose of warfarin in people with Atrial Fibrillation.,TT,
1184165651,rs1043550,CALU,warfarin,23656803,Dosage,no,"No significant differences in therapeutic warfarin dose (mg/wk) or error in predicted dose were seen between any of the genotypes (AA, AG, GG). Note that the study cohort differed from Hardy-Weinberg equilibrium.",Allele A is not associated with dose of warfarin as compared to allele G.,A,
827603022,rs9923231,VKORC1,warfarin,15930419,Dosage,yes,This variant is part of the a low-dose haplotype group (A).,Allele T is associated with decreased dose of warfarin.,T,
1450942212,rs7412,APOE,warfarin,31854268,Dosage,yes,,"Genotype CC is associated with increased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to genotypes CT + TT.",CC,
1450942260,rs1045642,ABCB1,warfarin,31854268,Dosage,no,"ABCB1 GG wild-type required a mean dose of 2.96 ± 1.27 mg/d, whereas heterozygotes (GA) and homozygotes (AA) were found to require lower doses (2.67 ± 0.93 and 2.43 ± 0.80 mg/d, respectively, p = 0.122). but this was not significant.","Genotype AA is not associated with decreased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis.",AA,
1184509852,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,22854539,Dosage,yes,,CYP2C9 *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2/*3 + *3/*3,
1448104687,rs9923231,VKORC1,warfarin,27182616,Dosage,yes,"The average daily warfarin dose required for maintenance therapy in patients with T allele was 4.26±1.24, whereas it was 4.80±1.55in those without this mutation.",Allele T is associated with decreased dose of warfarin in children as compared to allele C.,T,Pediatric
827864562,rs1057910,CYP2C9,warfarin,21228733,Dosage,yes,"This SNP defines CYP2C9*3. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1.",Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
827864558,rs2108622,CYP4F2,warfarin,21228733,,no,"A significant association between genotype and dose was not found in this study; however, the trend for this association ""was consistent with the literature"".",Allele C is not associated with decreased dose of warfarin as compared to allele T.,C,
1448104673,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,27182616,Dosage,yes,"The average daily warfarin dose required for maintenance therapy in patients with the CYP2C9*3was 3.98±1.13, whereas it was 4.40±1.39 in those without this mutation.",CYP2C9 *3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.,*3,Pediatric
827864550,rs339097,CALU,warfarin,21228733,Dosage,no,"A p value of 0.04 was given for dose- genotype association, but the authors stated that this association did not reach significanc in multiple regression testing (p = 0.066), and that was likely due to insufficient power.Variant allele carriers required 14.1 mg/week more warfarin than AA.",Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.,AG + GG,
827864552,rs9923231,VKORC1,warfarin,21228733,Dosage,yes,,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
827864546,rs1799853,CYP2C9,warfarin,21228733,Dosage,yes,"This SNP defines CYP2C9*2. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1.",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1448104659,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,27182616,Dosage,no,"The average daily warfarin dose required for maintenance therapy in patients with the CYP2C9*2 was 3.67±1.38, whereas it was 4.35±1.25 in those without this mutation.",CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.,*2,Pediatric
827602228,rs1057910,CYP2C9,warfarin,18305455,Dosage,yes,CYP2C9*3 was associated with a 33% (95% confidence interval 29¿37%) decrement in warfarin dose per allele.,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1184510108,"CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5",CYP2C9,warfarin,22274142,Dosage,yes,This variant is analyzed along with VKORC1 variants.,CYP2C9 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5,
1184510021,rs9934438,VKORC1,warfarin,22549502,Dosage,yes,in Korean patients with mechanical cardiac valves.,Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1445401050,rs72547529,VKORC1,warfarin,20615525,Dosage,not stated,"Of the 11 patients on high doses of warfarin, sequencing of VKORC1 revealed a nonsynonymous VKORC1 V66M mutation in two warfarin resistant patients, both of African-descent.",Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1184510039,rs2108622,CYP4F2,warfarin,22549502,Dosage,yes,in Korean patients with mechanical cardiac valves.,Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.,TT,
1445401042,rs9923231,VKORC1,warfarin,20615525,Dosage,not stated,The VKORC1--1639 (3673) G>A polymorphism associated with warfarin sensitivity was present in 48 out of 51 (94.1%) patients on low dose warfarin.,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1184510043,rs699664,GGCX,warfarin,22549502,Dosage,no,in Korean patients with mechanical cardiac valves.,Allele C is not associated with dose of warfarin as compared to allele T.,C,
1184510047,rs2290228,CALU,warfarin,22549502,Dosage,no,in Korean patients with mechanical cardiac valves.,Allele A is not associated with decreased dose of warfarin as compared to allele G.,A,
1445401065,rs72547529,VKORC1,warfarin,19663669,Dosage,not stated,3 warfarin resistant g.1331G>A (p.V66M) carriers were identified (1 in ~100 individuals) suggesting this variant is associated with warfarin resistance.,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1445401057,rs72547529,VKORC1,warfarin,15630486,Dosage,not stated,The VKORC1 V66M variant is identified in warfarin resistant patient.,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1184510232,"CYP2C9*1, CYP2C9*3, CYP2C9*13",CYP2C9,warfarin,21782804,Dosage,not stated,"This is a Korean patient with CYP2C9*3/*13 and VKORC1 1173TT genotypes who had slower than normal warfarin metabolism, resulting in the need to administer an extremely low dose of warfarin (4 mg/week) in order to achieve the target INR value.",CYP2C9 *3/*13 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3/*13,
1184510136,rs2108622,CYP4F2,warfarin,22192158,Dosage,yes,"in the meta-analysis. Carriers of CT, TT genotypes required 10.0% (95% confidence interval(CI) 4.0-15.0) and 21.0% (95% CI 9.0-33.0) higher warfarin doses respectively as compared to the CC genotype (P value <0.05). In addition, T carriers required 11.0% (95% CI 6.0-17.0) higher warfarin dose than CC genotype.",Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
1448268118,"CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,24088130,Dosage,not stated,"This study assessed the impact of using genotype-guided dosing on anticoagulation visits in adults taking warfarin. Genotype-guided dosing did NOT improve number of anticoagulation visits or time in therapeutic range as compared to clinical only dosing. However, the algorithm used by this study to determine warfarin dose included these variants.",CYP2C9 *2 + *3 are associated with dose of warfarin.,*2 + *3,
1448268112,rs9923231,VKORC1,warfarin,24088130,Dosage,not stated,"This study assessed the impact of using genotype-guided dosing on anticoagulation visits in adults taking warfarin. Genotype-guided dosing did NOT improve number of anticoagulation visits or time in therapeutic range as compared to clinical only dosing. However, the algorithm used by this study to determine warfarin dose included this variant. Please note that alleles have been complemented to the plus chromosomal strand.",Allele T is associated with dose of warfarin.,T,
1184510155,rs2108622,CYP4F2,warfarin,22172097,Dosage,yes,,Genotype CT is associated with increased dose of warfarin as compared to genotype CC.,CT,
1184510186,rs9934438,VKORC1,warfarin,22075505,Dosage,yes,in older patients (age >75 years).,Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
1448108305,rs699664,GGCX,warfarin,27262824,Dosage,no,,Genotypes CT + TT is not associated with dose of warfarin in children as compared to genotype CC.,CT + TT,Pediatric
982037860,rs1057910,CYP2C9,warfarin,20072124,Dosage,yes,This variant defines CYP2C9*3.,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1448108296,rs2108622,CYP4F2,warfarin,27262824,Dosage,no,,Genotypes CT + TT is not associated with dose of warfarin in children as compared to genotype CC.,CT + TT,Pediatric
982037919,rs2884737,VKORC1,warfarin,20072124,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
982037888,rs17880887,VKORC1,warfarin,20072124,Dosage,no,,Allele T is not associated with decreased dose of warfarin as compared to allele G.,T,
982037894,rs9923231,VKORC1,warfarin,20072124,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1449005482,rs9332131,CYP2C9,warfarin,28685643,"Dosage,""Efficacy""",not stated,"Case report is of a 38-year-old African–American woman with pulmonary embolism and carrier of the rare CYP2C9*5 (rs28371686 G), CYP2C9*6 (rs9332131 del) alleles and required an average of 5.3 mg/day of warfarin during the dose initiation phase and decreased maintenance dose requirement of 2.5–3.6 mg/day. Despite JD’s VKORC1 rs9923231 GG genotype, indicating insensitivity, actual warfarin dose was 22–25% and 47–49% lower, respectively than if estimating a warfarin dose utilizing clinical factors only.",Allele del is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele A.,del,
1449005488,rs28371686,CYP2C9,warfarin,28685643,"Dosage,""Efficacy""",not stated,"Case report is of a 38-year-old African–American woman with pulmonary embolism and carrier of the rare CYP2C9*5 (rs28371686 G), CYP2C9*6 (rs9332131 del) alleles and required an average of 5.3 mg/day of warfarin during the dose initiation phase and decreased maintenance dose requirement of 2.5–3.6 mg/day. Despite JD’s VKORC1 rs9923231 GG genotype, indicating insensitivity, actual warfarin dose was 22–25% and 47–49% lower, respectively than if estimating a warfarin dose utilizing clinical factors only.",Allele G is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele C.,G,
827784097,rs1877724,EPHX1,warfarin,21192345,Dosage,yes,"Patients homozygous for the variant allele of (TT) required approximately 3.0 mg/day compared with the wild type (CC) and heterozygous patients who required approximately 3.4 mg/day warfarin maintenance dose. The variant contribution is small, explaining only an additional 0.8% of the dose variability.",Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.,TT,
1449005494,rs9923231,VKORC1,warfarin,28685643,"Dosage,""Efficacy""",not stated,"Case report is of a 38-year-old African–American woman with pulmonary embolism and carrier of the rare CYP2C9*5 (rs28371686 G), CYP2C9*6 (rs9332131 del) alleles and required an average of 5.3 mg/day of warfarin during the dose initiation phase and decreased maintenance dose requirement of 2.5–3.6 mg/day. Despite JD’s VKORC1 rs9923231 GG genotype, indicating insensitivity, actual warfarin dose was 22–25% and 47–49% lower, respectively than if estimating a warfarin dose utilizing clinical factors only.",Genotype GG is not associated with dose of warfarin in Pulmonary Embolism as compared to allele C.,GG,
1184997889,rs2501873,NR1I3,warfarin,25356900,Dosage,yes,"Please note this association is found for a combination of two variants. Patients with rs2501873 (TT) and at least one variant allele in HNF4a rs3212198 (T allele) required higher warfarin doses (6.2±2.4mg) than those with other combinations (5.3± 1.7mg, ranging from 5.2 ±1.9 to 5.5± 1.9mg). These variant combination explained 1.7% of the overall interindividual variability in warfarin dose requirements among the study patients in a multivariate regression analysis (p=0.019).",Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.,TT,
982037942,rs2108622,CYP4F2,warfarin,20072124,Dosage,no,,Allele T is not associated with decreased dose of warfarin as compared to allele C.,T,
982037960,rs7412,APOE,warfarin,20072124,Dosage,no,,Allele T is not associated with decreased dose of warfarin as compared to allele C.,T,
1184997918,rs3212198,HNF4A,warfarin,25356900,Dosage,yes,"Please note this association is found for a combination of two variants. Patients with rs2501873 (TT) and at least one variant allele in HNF4a rs3212198 (T allele) required higher warfarin doses (6.2±2.4mg) than those with other combinations (5.3± 1.7mg, ranging from 5.2 ±1.9 to 5.5± 1.9mg). These variant combination explained 1.7% of the overall interindividual variability in warfarin dose requirements among the study patients in a multivariate regression analysis (p=0.019).",Allele T is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.,T,
982037951,rs429358,APOE,warfarin,20072124,Dosage,no,,Allele T is not associated with decreased dose of warfarin as compared to allele C.,T,
1448255577,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,27453700,Dosage,not stated,,CYP2C9 *2 is associated with dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1.,*2,Pediatric
1184473659,"CYP2C9*1, CYP2C9*14",CYP2C9,warfarin,24956244,Dosage,not stated,This patient also carries the warfarin insensitive VKORC1 -1639GG and CYP4F2 433Met/Met genotypes.,CYP2C9 *1/*14 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*14,
982038144,rs1799853,CYP2C9,warfarin,11966680,Dosage,not stated,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1447223182,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,22571356,Dosage,no,"CYPC9*3 variant 4.2 mg, wild type 4.0mg.",CYP2C9 *3 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3,
1447223171,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,22571356,Dosage,yes,"CYPC9*2 variant 3.6 mg, wild type 4.0mg.",CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2,
1449251596,rs2108622,CYP4F2,warfarin,28049362,Dosage,no,,Allele T is not associated with dose of warfarin as compared to allele C.,T,
1449251734,rs6046,F7,warfarin,28049362,Dosage,no,,Allele A is not associated with dose of warfarin as compared to allele G.,A,
1184654330,rs9923231,VKORC1,warfarin,24330000,"Dosage,""Efficacy""",yes,"A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. A two-fold difference in dose between children with the CC and TT genotype was found. A table predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype is presented in the paper. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. Note: alleles have been complemented to the plus chromosomal strand.",Genotype CC is associated with increased dose of warfarin in children with Heart Diseases as compared to genotype TT.,CC,Pediatric
1448615563,rs2108622,CYP4F2,warfarin,28429387,Dosage,yes,Alleles have been complemented to the positive chromosomal strand.,Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.,CC,
1184654356,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,24330000,"Dosage,""Efficacy""",yes,"A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - no children had the *3/*3 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and CYP2C9*3 as rs1057910.",CYP2C9 *3/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.,*3/*3,Pediatric
1448615540,rs142410335,MIR133B,warfarin,28429387,Dosage,no,,Genotype AA is not associated with dose of warfarin as compared to genotype A/del.,AA,
1448615546,rs1057910,CYP2C9,warfarin,28429387,Dosage,yes,,Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.,AA,
1184654374,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,24330000,"Dosage,""Efficacy""",not stated,"A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - n=2 children had the *2/*3 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and *3 as rs1057910.",CYP2C9 *2/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.,*2/*3,Pediatric
1448615525,rs12714145,GGCX,warfarin,28429387,Dosage,no,,Genotypes CC + CT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype TT.,CC + CT,
1448615516,rs9923231,VKORC1,warfarin,28429387,Dosage,yes,Alleles have been complemented to the positive strand.,Genotype TT is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.,TT,
1184654456,rs2108622,CYP4F2,warfarin,24330000,"Dosage,""Efficacy""",no,"A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Though there was a trend for a higher dose per T allele, CYP4F2 genotype was not retained in the final model. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children.",Allele T is not associated with increased dose of warfarin in children with Heart Diseases as compared to allele C.,T,Pediatric
1184654392,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,24330000,"Dosage,""Efficacy""",yes,"A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - n=23 children had the *1/*3 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and *3 as rs1057910.",CYP2C9 *1/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.,*1/*3,Pediatric
1184654401,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,24330000,"Dosage,""Efficacy""",yes,"A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - n=20 children had the *1/*2 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and *3 as rs1057910.",CYP2C9 *1/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.,*1/*2,Pediatric
1448615355,rs699664,GGCX,warfarin,28429387,Dosage,no,,Genotypes CC + CT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype TT.,CC + CT,
827783799,rs9923231,VKORC1,warfarin,21174619,Dosage,yes,[stat_test: kruskal-wallis],Genotype CC is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to genotype TT.,CC,
978614496,rs699664,GGCX,warfarin,22676192,"Dosage,""Metabolism/PK""",not stated,"in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231, complemented here for the plus strand to give allele T as the variant allele), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664).",Allele T is associated with dose of warfarin.,T,
982036901,rs1799853,CYP2C9,warfarin,19387626,Dosage,not stated,"using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*2. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram.",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
978614465,rs2108622,CYP4F2,warfarin,22676192,"Dosage,""Metabolism/PK""",not stated,"in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664).",Allele T is associated with dose of warfarin.,T,
982036874,rs1057910,CYP2C9,warfarin,19387626,Dosage,not stated,"using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*3. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram.",Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1446534354,rs9332238,CYP2C9,warfarin,26265036,Dosage,yes,"The G allele was strongly associated with high warfarin dose (G allele, OR: 6.8 [5.0–9.1]; p = 4.4 × 10-13) in Brazilian patients. This variant is in virtually perfect LD with CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910).",Allele G is associated with increased dose of warfarin as compared to allele A.,G,
978614455,rs9923231,VKORC1,warfarin,22676192,"Dosage,""Metabolism/PK""",not stated,"in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231, complemented here for the plus strand to give allele T as the variant allele), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664).",Allele T is associated with dose of warfarin.,T,
978614436,CYP2C9*3,CYP2C9,warfarin,22676192,"Dosage,""Metabolism/PK""",not stated,"in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664).",CYP2C9 *3 is associated with dose of warfarin.,*3,
982036951,rs28371686,CYP2C9,warfarin,19387626,Dosage,not stated,"using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*5. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram.",Allele G is associated with decreased dose of warfarin as compared to allele C.,G,
1450939860,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,31854268,Dosage,yes,"Minor allele frequency was 5.1%, with only one homozygote (*3/*3). *2 and *3 were tested but very small numbers of *2 (2 heterozygotes and no homozygotes, frequency of 0.5%) meant that *2 was not significant.","CYP2C9 *3 is associated with decreased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to CYP2C9 *1/*1.",*3,
978614420,CYP2C9*8,CYP2C9,warfarin,22676192,"Dosage,""Metabolism/PK""",not stated,"in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664).",CYP2C9 *8 is associated with dose of warfarin.,*8,
982036966,rs28371686,CYP2C9,warfarin,19387626,Dosage,not stated,"using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*5. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram.",Allele G is associated with decreased dose of warfarin as compared to allele C.,G,
982036958,rs56165452,CYP2C9,warfarin,19387626,Dosage,not stated,"using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*4. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram.",Allele C is associated with decreased dose of warfarin as compared to allele T.,C,
982036914,rs510317,F7,warfarin,19387626,Dosage,yes,"using the extreme-discordant-phenotype (EDP) methodology. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram.",Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.,AA + AG,
982036934,rs9923231,VKORC1,warfarin,19387626,Dosage,not stated,"using the extreme-discordant-phenotype (EDP) methodology. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram.",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1451120160,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,31395958,Dosage,yes,,CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3,
982036973,rs28371685,CYP2C9,warfarin,19387626,Dosage,not stated,"using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*11. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram.",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1183704662,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,24019055,Dosage,yes,Genetic variants in CYP2C9 contributed to 12.4% of the variation in warfarin dose.,CYP2C9 *1/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3 + *2/*3,
613977249,rs2359612,"PRSS53,""VKORC1""",warfarin,16270629,Dosage,yes,It is in strong linkage disequilibrium (r2>0.9) with rs9923231.,Allele A is associated with decreased dose of warfarin.,A,
1183704700,rs11676382,GGCX,warfarin,24019055,Dosage,yes,The authors report that the rs11676382 allele accounted for 0.6% of the variability in warfarin dose. There were no individuals in the sample of genotype GG.,Genotype CG is associated with decreased dose of warfarin as compared to genotype CC.,CG,
1183704687,rs2884737,VKORC1,warfarin,24019055,Dosage,yes,There were no individuals of genotype CC.,Genotype AA is associated with increased dose of warfarin as compared to genotype AC.,AA,
1444666225,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,25312789,Dosage,yes,"This is using Classification I. It divided the individuals into three dose ranges: <=21 mg, 21–49 mg, and >= 49 mg/week.",CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*2,
1444666244,rs429358,APOE,warfarin,25312789,Dosage,yes,"The APOE *e4 was associated with lower warfarin dose. Doses of e4 carriers (41.5±18.5) were 21 % lower than doses of e4 non-carriers (52.5±37.5 mg). This is using Classification I. It divided the individuals into three dose ranges: <=21 mg, 21–49 mg, and >= 49 mg/week.",Genotypes CC + CT is associated with decreased dose of warfarin as compared to genotype TT.,CC + CT,
1444666251,rs1045642,ABCB1,warfarin,25312789,Dosage,yes,Classification II divided the individuals into two dose ranges: <70 mg and >=70 mg warfarin/week,Allele A is associated with increased dose of warfarin as compared to allele G.,A,
1450186421,rs2108622,CYP4F2,"acenocoumarol,""warfarin""",30506689,Dosage,yes,"The meta-analysis showed that this variant (CYP4F2*3) was consistently associated with an increase in mean coumarin dose (+9% (95%CI 7-10%), with a higher effect in females, in patients taking acenocoumarol and in Whites and Asians, but with a low effect size and not in Blacks or other ethnic groups.",Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC.,CT + TT,
1444666236,rs9923231,VKORC1,warfarin,25312789,Dosage,yes,"This is using Classification I. It divided the individuals into three dose ranges: <=21 mg, 21–49 mg, and >= 49 mg/week.",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1183704872,rs9934438,VKORC1,warfarin,24019055,Dosage,yes,"Seven SNPs in VKORC1 were in strong LD: rs7294, rs2359612, rs8050894, rs9934438, rs2884737, rs9923231, rs7196161. Haplotype ACGCTGT had the highest frequency (0.74) and was associated with the second highest mean daily dose (5.46 mg/day) while the GCGCTGT haplotype (0.09 frequency) was associated with the highest mean daily dose (5.83 mg/day). The authors report that genetic variants in VKORC1 accounted for 32.4% of the variability in warfarin dose. In univariate analysis the authors report that rs9923231 genotype alone contributed 27.5% of the variation in the require dose.",Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.,GG,
1183704846,rs7196161,VKORC1,warfarin,24019055,Dosage,yes,"Seven SNPs in VKORC1 were in strong LD: rs7294, rs2359612, rs8050894, rs9934438, rs2884737, rs9923231, rs7196161. Haplotype ACGCTGT had the highest frequency (0.74) and was associated with the second highest mean daily dose (5.46 mg/day) while the GCGCTGT haplotype (0.09 frequency) was associated with the highest mean daily dose (5.83 mg/day). The authors report that genetic variants in VKORC1 accounted for 32.4% of the variability in warfarin dose.",Genotype GG is associated with decreased dose of warfarin as compared to genotypes AA + AG.,GG,
1183704839,rs2108622,CYP4F2,warfarin,24019055,Dosage,yes,The authors report that rs21086622 genotype accounted for 1.9% of the variability in warfarin dose.,Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.,TT,
1183704858,rs9923231,VKORC1,warfarin,24019055,Dosage,yes,"Seven SNPs in VKORC1 were in strong LD: rs7294, rs2359612, rs8050894, rs9934438, rs2884737, rs9923231, rs7196161. Haplotype ACGCTGT had the highest frequency (0.74) and was associated with the second highest mean daily dose (5.46 mg/day) while the GCGCTGT haplotype (0.09 frequency) was associated with the highest mean daily dose (5.83 mg/day). The authors report that genetic variants in VKORC1 accounted for 32.4% of the variability in warfarin dose.",Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.,CC,
982037339,rs9923231,VKORC1,warfarin,19745563,Dosage,yes,"This variant is the tag for low dose H1 haplotype and the H*a haplotype described in this paper differentiating them from H7 and H*b which were high dose haplotypes. No H7-H7 diplotypes were reported. The major VKORC1 diplotypes were H1-H1 (62%), H1-H7 (18%) and H1-H*b (10%). Allele complemented to plus chromosomal strand. Warfarin dose requirements were significantly lower in patients with VKORC1 H1-H1 and H1-H*a diplotypes compared to patients harboring the H1-H7 and H1-H*b diplotypes.",Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.,TT,
1183704894,rs2359612,VKORC1,warfarin,24019055,Dosage,yes,"Seven SNPs in VKORC1 were in strong LD: rs7294, rs2359612, rs8050894, rs9934438, rs2884737, rs9923231, rs7196161. Haplotype ACGCTGT had the highest frequency (0.74) and was associated with the second highest mean daily dose (5.46 mg/day) while the GCGCTGT haplotype (0.09 frequency) was associated with the highest mean daily dose (5.83 mg/day). The authors report that genetic variants in VKORC1 accounted for 32.4% of the variability in warfarin dose.",Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.,GG,
1183704889,rs8050894,VKORC1,warfarin,24019055,Dosage,yes,"Seven SNPs in VKORC1 were in strong LD: rs7294, rs2359612, rs8050894, rs9934438, rs2884737, rs9923231, rs7196161. Haplotype ACGCTGT had the highest frequency (0.74) and was associated with the second highest mean daily dose (5.46 mg/day) while the GCGCTGT haplotype (0.09 frequency) was associated with the highest mean daily dose (5.83 mg/day). The authors report that genetic variants in VKORC1 accounted for 32.4% of the variability in warfarin dose.",Genotype CC is associated with increased dose of warfarin as compared to genotypes CG + GG.,CC,
1446533819,rs749671,VKORC1,warfarin,26265036,Dosage,yes,"The G allele was strongly associated with high warfarin dose (G allele, OR: 20.4 [14.3–29.0]; p = 1.08 × 10-33) in Brazilian patients.",Allele G is associated with increased dose of warfarin as compared to allele A.,G,
1449269204,rs1057910,CYP2C9,warfarin,28973620,Dosage,not stated,,Allele C is associated with dose of warfarin as compared to allele A.,C,
1449269199,rs1799853,CYP2C9,warfarin,28973620,Dosage,not stated,,Allele T is associated with dose of warfarin as compared to allele C.,T,
1447680563,rs2108622,CYP4F2,warfarin,26739746,Dosage,yes,The CYP4F2 variant only plays a small effect on warfarin mean weekly dose (MWD). It explained only a further 0.5 % of the MWD variance.,Allele T is associated with dose of warfarin as compared to allele C.,T,
1447680551,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,26739746,Dosage,yes,,CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *3,
1447680533,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,26777610,Dosage,yes,,CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3,
769245704,rs61162043,VKORC1,warfarin,21270790,Dosage,yes,,Allele G is associated with increased dose of warfarin.,G,
769245708,rs7089580,CYP2C9,warfarin,21270790,Dosage,yes,,Allele T is associated with increased dose of warfarin.,T,
1448122820,"CYP2C19*1, CYP2C19*2, CYP2C19*3",CYP2C19,warfarin,27356304,Dosage,yes,"The warfarin maintenance doses of patients with CYP2C19*1/*1 were also significantly higher than those with other five genotypes with *2, *3 (all P < 0.05).",CYP2C19 *1/*2 + *1/*3 are associated with increased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C19 *2/*2 + *2/*3.,*1/*2 + *1/*3,
1448122772,"CYP2C19*1, CYP2C19*2, CYP2C19*3",CYP2C19,warfarin,27356304,Dosage,yes,"The warfarin maintenance doses of patients with CYP2C19*1/*1 were significantly higher than those with other five genotypes with *2, *3 (all P < 0.05).",CYP2C19 *1/*1 is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.,*1/*1,
1448257194,rs9923231,VKORC1,warfarin,27488176,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
637879876,rs339097,CALU,warfarin,20200517,Dosage,yes,,Allele G is associated with increased dose of warfarin.,G,
1444695613,rs12714145,GGCX,warfarin,25681132,Dosage,no,,Genotypes CT + TT is not associated with dose of warfarin as compared to genotype CC.,CT + TT,
827649690,rs7294,"PRSS53,""VKORC1""",warfarin,16611750,Dosage,yes,,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1449157667,rs1143671,SLC15A2,warfarin,29234073,Dosage,yes,,Genotype TT is associated with decreased dose of warfarin as compared to genotype CC.,TT,
982033533,rs1057910,CYP2C9,warfarin,10961881,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
769277920,rs9923231,VKORC1,warfarin,17049586,Dosage,yes,,Genotype TT is associated with decreased dose of warfarin as compared to genotype CT.,TT,
1447952622,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,26877068,Dosage,yes,"in European americans, but not African americans.",CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2,
1444608101,rs7089580,CYP2C9,warfarin,25499099,Dosage,yes,,Genotype AT is associated with increased clearance of warfarin as compared to genotype AA.,AT,
982037879,rs1799853,CYP2C9,warfarin,20072124,Dosage,yes,This variant defines CYP2C9*2.,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1449269209,rs2108622,CYP4F2,warfarin,28973620,Dosage,not stated,,Allele T is associated with dose of warfarin as compared to allele C.,T,
1449157694,rs7311358,SLCO1B3,warfarin,29234073,Dosage,yes,,Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.,AA,
982032955,rs1057910,CYP2C9,warfarin,18535201,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
982032947,rs4917639,CYP2C9,warfarin,18535201,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
982033113,rs10509680,CYP2C9,warfarin,20833655,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele G.,T,
1447573633,rs9934438,VKORC1,warfarin,19074728,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1447519319,rs9923231,VKORC1,warfarin,23602689,Dosage,not stated,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
827864560,rs7412,"APOC1,""APOE""",warfarin,21228733,Dosage,yes,,Allele T is associated with decreased dose of warfarin in people with haplotype epsilon2.,T,
982044357,rs2884737,VKORC1,warfarin,16611750,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
827690626,rs4653436,EPHX1,warfarin,21593757,Dosage,no,in an italian population.,Allele A is not associated with dose of warfarin.,A,
827567338,rs11150606,VKORC1,warfarin,15883587,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele T.,C,
827567321,rs2359612,VKORC1,warfarin,15883587,Dosage,yes,,Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1447520009,rs9923231,VKORC1,warfarin,26445138,Dosage,yes,,Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
1183701883,rs1799853,CYP2C9,warfarin,8004131,Metabolism/PK,not stated,Impaired metabolism was found for S-warfarin. T= CYP2C9*2; C= CYP2C9*1.,Allele T is associated with decreased metabolism of warfarin as compared to allele C.,T,
608431732,rs1057910,CYP2C9,warfarin,19794411,Dosage,yes,,Allele C is associated with decreased dose of warfarin.,C,
981483998,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,20653676,"Dosage,""Efficacy""",yes,2.1 mg/day vs 2.9 mg/day,CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to CYP2C9 *1/*1.,*1/*3 + *3/*3,
982043913,CYP2C9*2,CYP2C9,warfarin,15883587,Dosage,yes,,CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*2,
982037353,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,19745563,Dosage,yes,,CYP2C9 *1/*2 + *1/*3 is associated with decreased dose of warfarin when treated with warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *1/*3,
981344716,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,12496751,"Dosage,""Metabolism/PK""",yes,Clearance of the S-warfarin enantiomer only is significant (10% of clearance seen by homozygous wild-type patients). Clearance of the R-warfarin enantiomer did not show differences among genotypes. The mean maintenance dose for patients homozygous for the *3 haplotype was 4.5 times lower than that of the *1 haplotype.,CYP2C9 *3 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.,*3,
981345093,CYP2C9*3,CYP2C9,warfarin,12496751,Metabolism/PK,yes,"Patients with *3 alleles are more frequently found in the low dose group, <26.25 mg/week. Four of the 22 subjects with one or more *3 alleles were found in the medium dose group, 26.25-43.75 mg/week, and none were found in the high dose group, >43.75 mg/week.",CYP2C9 *3 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.,*3,
982047409,CYP2C9*1,CYP2C9,warfarin,22010099,"Dosage,""Metabolism/PK""",not stated,Only one participant had the *2/*2 genotype,CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*2.,*1/*1,Pediatric
608431785,rs9332131,CYP2C9,warfarin,20072124,Dosage,yes,,Allele del is associated with decreased dose of warfarin.,del,
1183700033,rs2108622,CYP4F2,warfarin,19207028,Dosage,yes,MWWD (Mean weekly warfarin dose): CC 20.54 mg/wk;CT: 24.19 mg/wk;TT:38.44 mg/wk. About 7% of mean weekly warfarin dose variance is explained by the genotype at this SNP.,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
655388073,rs7294,VKORC1,warfarin,16676068,"Dosage,""Metabolism/PK""",yes,,Allele T is associated with increased dose of warfarin.,T,
655388076,rs9934438,VKORC1,warfarin,16676068,"Dosage,""Metabolism/PK""",yes,,Allele A is associated with decreased dose of warfarin.,A,
608431741,rs12714145,GGCX,warfarin,19794411,Dosage,no,,Allele T is not associated with dose of warfarin.,T,
608431764,rs2234922,EPHX1,warfarin,19794411,,no,,Allele G is not associated with dose of warfarin.,G,
1184510035,rs4244285,CYP2C19,warfarin,22549502,Dosage,no,in Korean patients with mechanical cardiac valves.,Allele A is not associated with decreased dose of warfarin as compared to allele G.,A,
769246303,rs2108622,CYP4F2,warfarin,20442691,Dosage,yes,,Genotype CC is associated with decreased dose of warfarin as compared to genotype CT.,CC,
827783868,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,21174619,Dosage,yes,"Genotyped for rs1799853 and rs1057910. Combined *2/*2, *2/*3 and *3*3 were compared with carriers of the *1 allele. [stat_test: kruskal-wallis]",CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.,*3/*3,
827783860,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,21174619,Dosage,yes,"Genotyped for rs1799853 and rs1057910. Combined *2/*2, *2/*3 and *3*3 were compared with carriers of the *1 allele. [stat_test: kruskal-wallis]",CYP2C9 *2/*2 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.,*2/*2,
827783872,"CYP4F2*1, CYP4F2*3",CYP4F2,warfarin,21174619,Dosage,yes,Genotyped for rs2108622. [stat_test: kruskal-wallis],CYP4F2 *3/*3 is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP4F2 *1/*1.,*3/*3,
827783863,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,21174619,Dosage,yes,"Genotyped for rs1799853 and rs1057910. Combined *2/*2, *2/*3 and *3*3 were compared with carriers of the *1 allele. [stat_test: kruskal-wallis]",CYP2C9 *2/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.,*2/*3,
827925130,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,22528326,"Dosage,""Metabolism/PK""",yes,"No *3*3 homozygotes were observed. Daily maintenance dose range for *1*1 was 3.00 to 3.42mg/day, dose range for *1*3 was 1.47 to 2.55mg/day.",CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Thromboembolism as compared to CYP2C9 *1/*1.,*1/*3,
827845854,rs11636419,CYP1A2,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose.,Allele G is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele A.,G,
981239471,rs104894541,VKORC1,warfarin,14765194,Dosage,not stated,This rare (<0.1%) missense mutation in VKORC1 gene confers warfarin resistance phenotype. Individuals carrying this mutation require higher dose of warfarin (32-36mg/d). VKORC1:R58G; Arg58Gly,Allele C is associated with increased dose of warfarin as compared to allele T.,C,
827845898,rs28371759,CYP3A4,warfarin,22248286,Dosage,no,No association was found between this variant and warfarin-maintenance dose.,Allele G is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele A.,G,
827807419,CYP2C9*1,CYP2C9,warfarin,18322281,Dosage,yes,"as compared to *2*2 or *3*3 or *2*3 with *1*2 and *1*3 requiring intermediate doses. This was most marked at day 28 to end of follow-up with average doses of 5.18mg/day for *1*1, 4.25mg/day for *1*2 or *1*3 and 3.36mg/day for *2*2 or *3*3 or *2*3.",CYP2C9 *1/*1 is associated with increased dose of warfarin.,*1/*1,
1449269193,rs9923231,VKORC1,warfarin,28973620,Dosage,not stated,,Allele A is associated with dose of warfarin as compared to allele G.,A,
827863698,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,21692828,"Other,""Metabolism/PK""",not stated,"For S-Warfarin in a model that included bodyweight, age and sex.",CYP2C9 *2 is associated with decreased clearance of warfarin as compared to CYP2C9 *1.,*2,
827863693,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,21692828,"Other,""Metabolism/PK""",not stated,"For S-Warfarin in a model that included bodyweight, age and sex.",CYP2C9 *3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1.,*3,
827814740,rs1057910,CYP2C9,warfarin,21148049,Dosage,yes,,Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1184483448,rs17650,ORM1,warfarin,23208322,Dosage,yes,ORM1 S carriers (G allele carriers) may require lower maintenance doses to achieve and maintain an optimal level of anticoagulation. This variant is evaluated along with CYP2C9 rs1057910 (*3) and VKORC1 rs7294.,Genotypes AG + GG is associated with decreased dose of warfarin as compared to genotype AA.,AG + GG,
1184756997,rs4653436,EPHX1,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,G,
827864556,rs429358,"APOC1,""APOE""",warfarin,21228733,Dosage,yes,,Allele T is associated with decreased dose of warfarin in people with haplotype epsilon2.,T,
827864548,rs7900194,CYP2C9,warfarin,21228733,Dosage,yes,"This SNP defines CYP2C9*8. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1.",Allele A is associated with decreased dose of warfarin as compared to allele G.,A,
1184483453,rs7294,VKORC1,warfarin,23208322,Dosage,yes,This variant is evaluated along with CYP2C9 rs1057910 (*3) and ORM1 rs17650.,Allele C is associated with decreased dose of warfarin as compared to allele T.,C,
981344709,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,12496751,"Dosage,""Metabolism/PK""",yes,Clearance of the S-warfarin enantiomer only is significant (33% of clearance seen by homozygous wild-type patients). Clearance of the R-warfarin enantiomer did not show differences among haplotypes. The mean maintenance dose for patients homozygous for the *2 haplotype was 1.9 times lower than that of the *1 haplotype.,CYP2C9 *2 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.,*2,
981345061,CYP2C9*2,CYP2C9,warfarin,12496751,Metabolism/PK,yes,"Patients with *2 alleles are more frequently found in the low or medium dose groups, <26.25 mg/week or 26.25-43.75 mg/week, respectively. Only one of the 21 subjects with one or more *2 alleles was found in the high dose group, >43.75 mg/week.",CYP2C9 *2 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.,*2,
1447586762,rs9923231,VKORC1,warfarin,20339978,Dosage,yes,,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
637879873,rs339097,CALU,warfarin,20200517,Dosage,yes,,Allele G is associated with increased dose of warfarin.,G,
982043919,CYP2C9*3,CYP2C9,warfarin,15883587,Dosage,yes,,CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*3,
982033292,rs1799853,CYP2C9,warfarin,10073515,"Dosage,""Efficacy"",""Toxicity""",not stated,"Reduced function alleles CYP2C9*2 and CYP2C9*3 are pooled together for analysis. ""Patients in the low-dose group were more likely to have difficulties at the time of induction of warfarin therapy (5.97 [2.26-15.82]) and have increased risk of major bleeding complications (rate ratio 3.68 [1.43-9.50]) when compared with randomly selected clinic controls.""",Allele T is associated with decreased dose of warfarin as compared to allele C.,T,
982044365,rs8050894,VKORC1,warfarin,16611750,Dosage,yes,,Allele G is associated with decreased dose of warfarin as compared to allele C.,G,
982034970,rs56165452,CYP2C9,warfarin,21228733,Dosage,yes,"This SNP defines CYP2C9*4. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1.",Genotype CT is associated with decreased dose of warfarin as compared to genotype TT.,CT,
1183690117,rs2108622,CYP4F2,warfarin,22855348,Efficacy,no,Patients in this study were treated with low dose (1-2mg/day) warfarin. No association was found between this SNP and response to warfarin (metabolism or prothrombin time (INR)).,Genotype CC is not associated with response to warfarin as compared to genotypes CT + TT.,CC,
1183700614,rs1057910,CYP2C9,warfarin,10509530,"Dosage,""Efficacy""",yes,"The mean dose of warfarin required to achieve target INR was 2.85 mg/day(SD 1.07) for *3 carriers(AC + CC) vs 4.10 mg/day(SD 1.51) for ""wild-type"" (AA).",Genotypes AC + CC is associated with decreased dose of warfarin in men as compared to genotype AA.,AC + CC,
1183700228,rs2108622,CYP4F2,warfarin,19297519,Dosage,yes,TT > CT > CC.,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1183697705,rs9934438,VKORC1,warfarin,23990957,Dosage,yes,"This SNP was presented as VKORC1 1173C>T. Patients carrying the A allele showed significantly lower doses of warfarin as compared to patients with the wildtype genotype, GG.",Genotypes AA + AG is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotype GG.,AA + AG,
1183701586,CYP2C9*6,CYP2C9,warfarin,15094935,Dosage,no,This was one case report. The patient was also reported to demonstrate impaired clearance of S-warfarin.,CYP2C9 *6/*6 is associated with decreased dose of warfarin.,*6/*6,
1183701549,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,16160068,Dosage,no,This was a pilot study to compare traditional and PGx-guided dosing.,CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*2,
1183701320,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,17989110,Dosage,not stated,Weekly maintenance doses were *1/*1: 37.3 mg; *1/*3 + *3/*3: 30.3 mg.,CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3 + *3/*3,
1183700648,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,15001971,Dosage,yes,This study addressed the induction phase (defined here as the first 24 days of therapy). *2 and *3 were assayed. Patients with at least one *2 required a 17% lower mean daily dose compared to *1/*1 patients.,CYP2C9 *1/*2 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *2/*2 + *2/*3,
1183700730,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,20375999,Dosage,yes,Each CYP2C9*2 allele resulted in a 15% (11-19%) decrease in therapeutic dose on Day 4 or 5 of therapy.,CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,*2,
1183700669,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,15001971,Dosage,yes,This study addressed the induction phase (defined here as the first 24 days of therapy). *2 and *3 were assayed. Patients with at least one *3 required a 40% lower mean daily dose compared to *1/*1 patients.,CYP2C9 *1/*3 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3 + *2/*3 + *3/*3,
1183697697,rs2108622,CYP4F2,warfarin,23990957,Dosage,yes,"This SNP was presented as CYP4F2 1297G>A. Patients with the TT allele showed significantly higher doses of warfarin as compared to patients carrying the wildtype allele, C. However, this effect was small as the difference in dose between wildtype (CC) and homozygous variant (TT) genotypes was 0.6 mg/day.",Genotypes CC + CT is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotype TT.,CC + CT,
1184510172,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,22075505,Dosage,yes,,CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3,
1447680210,rs4645943,MYC,warfarin,26249541,Dosage,yes,This variant was found to be significant in the multivariate analysis and accounted for approximately 2.8% of variability in warfarin dose.,Genotypes CT + TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype CC.,CT + TT,
982047415,CYP2C9*1,CYP2C9,warfarin,22010099,"Dosage,""Metabolism/PK""",not stated,Only one participant had the *2/*3 genotype,CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*3.,*1/*1,Pediatric
1184472857,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,24474498,Dosage,yes,,CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.,*1/*3,Pediatric
982047403,CYP2C9*1,CYP2C9,warfarin,22010099,"Dosage,""Metabolism/PK""",no,,CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*2.,*1/*1,Pediatric
1184473587,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,25001883,Dosage,yes,with an approximate decrease of daily dose of 0.82mg.,CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1.,*2,Pediatric
1184510348,rs5896,F2,warfarin,21320153,Dosage,no,"in a Southern Brazilian population of European ancestry. This F2 variant is not associated independently with warfarin dose. However, when it was included in the multiple linear regression (after controlling for covariates), statistically significant results were obtained.",Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.,TT,
1184511588,rs11676382,GGCX,warfarin,25042728,Dosage,yes,,Genotypes CG + GG is associated with decreased dose of warfarin as compared to genotype CC.,CG + GG,
1184473580,rs9923231,VKORC1,warfarin,25001883,Dosage,yes,with an approximate decrease of daily dose of 0.66mg.,Allele T is associated with decreased dose of warfarin in children as compared to allele C.,T,Pediatric
1184512426,rs7856096,FPGS,warfarin,25079360,Dosage,yes,In the combined cohort each minor allele of rs7856096 contributed to -5.81 mg/week change in predicted dose (p= 3.93E-5) using the IWPC algorithm.,Allele G is associated with decreased dose of warfarin as compared to allele A.,G,
1444936331,rs12714145,GGCX,warfarin,26106580,Dosage,no,This meta-analysis in Chinese patients showed no difference in mean daily warfarin dose (MDWD) for various genotypes of GGCX variant rs12714145.,Allele T is not associated with dose of warfarin as compared to genotype CC.,T,
1185002294,rs7294,VKORC1,warfarin,21635147,Dosage,yes,in the South African black population. This allele was analyzed along with VKORC1 rs7200749.,Allele T is associated with increased dose of warfarin as compared to allele C.,T,
1185002301,rs7200749,VKORC1,warfarin,21635147,Dosage,yes,in the South African black population. This allele was analyzed along with VKORC1 rs7294.,Allele A is associated with increased dose of warfarin as compared to allele G.,A,
1449164090,rs2645400,GATA4,warfarin,29298995,Dosage,no,Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation.,Allele G is not associated with dose of warfarin as compared to allele T.,G,
1447519671,rs2359612,VKORC1,warfarin,18466099,Dosage,yes,in European Americans and African Americans.,Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.,AA + AG,
1444694633,rs2108622,CYP4F2,warfarin,25594941,Dosage,no,158/220 patients had the target INR (1.5–2.5). The comparison of weekly warfarin maintenance dose was among patients of different genotypes. Differences in maintenance dose were not observed in patients with variant genotypes of CYP4F2 s2108622. Please note: the alleles are complemented to the + chromosomal strand.,Genotypes CT + TT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype CC.,CT + TT,
1446767176,rs2917677,NQO1,warfarin,26257249,Dosage,no,"Genotype frequencies at this SNP were not found to be in Hardy-Weinberg Equilibrium. Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. Please note, alleles have been complimented to the + strand.",Genotype CC is not associated with dose of warfarin as compared to genotypes CT + TT.,CC,
1447024584,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,14676821,Dosage,yes,,CYP2C9 *1/*3 + *2/*3 + *3/*3 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3 + *2/*3 + *3/*3 + *2/*2,
1444695622,"CYP2C19*1, CYP2C19*2, CYP2C19*17",CYP2C19,warfarin,25652102,Metabolism/PK,yes,Carriers of CYP2C19*17 showed on average 32 % higher R-warfarin clearance than carriers of CYP2C19*2. Patients with CYP2C19*1/*1 genotype had clearance values in-between these two groups. No statistically significant association was observed between CYP2C19 genotypes and the clearance of S-warfarin.,CYP2C19 *1/*17 + *17/*17 are associated with increased clearance of warfarin as compared to CYP2C19 *1/*2 + *2/*2.,*1/*17 + *17/*17,
1445296627,"CYP2C9*1, CYP2C9*2",CYP2C9,warfarin,26024874,Dosage,yes,"only in European Americans, but not African Americans. (20.6% vs 3.0% dose reduction per variant allele, interaction p value<0.001)",CYP2C9 *1/*2 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *2/*2,
1444608095,rs7089580,CYP2C9,warfarin,25499099,Dosage,yes,,Genotype AT is associated with increased dose of warfarin as compared to genotype AA.,AT,
1445296671,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,26024874,Dosage,yes,"in both European Americans and African Americans. The dose reduction per variant allele was comparable among European Americans (34.6% vs 34.4%, interaction P value=0.98) vs. African Americans.",CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*3 + *3/*3,
1444707383,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,14521618,Dosage,yes,in North-Italian patients.,CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*1/*2 + *2/*2 + *1/*3 + *3/*3,
1447519684,rs7294,VKORC1,warfarin,18466099,Dosage,yes,in European Americans.,Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.,CT + TT,
1447519652,"CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11",CYP2C9,warfarin,18466099,Dosage,yes,in European Americans.,CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *3 + *5 + *6 + *11,
1447520623,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,17324110,Dosage,yes,"in Caucasians, but not in African american patients.",CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *3,
1446848557,"CYP2C9*1, CYP2C9*3",CYP2C9,warfarin,26219158,Dosage,no,in Thai patients.,CYP2C9 *3 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*3,
1448267948,CYP2C9*3,CYP2C9,warfarin,26996562,Dosage,not stated,"This study undertook the development of a warfarin pharmacogenetic dosing algorithm and then compared it against other dosing algorithms. This variant was included in the algorithm. However, note that there was no significant difference in stable warfarin dose between patients with the *1/*1 genotype (3.8+/1.4 mg/day) and the *1/*3 genotype (2.6+/-0.5 mg/day); only 4 patients carried the *3 allele.",CYP2C9 *3 is associated with dose of warfarin in people with Stroke.,*3,
1448276433,"CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,21725053,Dosage,not stated,"These variants were included in an algorithm generated within this study, the WRAPID Dosing Algorithm.",CYP2C9 *2 + *3 are associated with dose of warfarin.,*2 + *3,
1448276496,rs9923231,VKORC1,warfarin,26710337,Dosage,not stated,"This study assessed whether a pharmacogenetic dosing algorithm, which included this variant as well as the CYP2C9*2, CYP2C9*3 and CYP4F2*3 variants, is superior in overall anticoagulation control when compared to clinical standard of care. Please note that alleles have been complemented to the plus chromosomal strand.",Allele T is associated with dose of warfarin.,T,
1448276172,rs2359612,VKORC1,warfarin,21326313,Dosage,yes,"The mean warfarin dose was higher in patients with the GG genotype (5.0+/-1.0 mg/day) as compared to those with the AG (4.0+/-2.0 mg/day) or AA genotype (3.0+/-1.5 mg/day). This variant was in linkage disequilibrium with rs7294, rs9934438 and rs8050894.",Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.,GG,
1448109658,rs9934438,VKORC1,warfarin,27121899,Dosage,not stated,This variant annotation is part of a dosing algorithm table based on 8 genetic variants.,Allele A is associated with dose of warfarin as compared to allele G.,A,
1448109688,rs9332131,CYP2C9,warfarin,27121899,Dosage,not stated,This variant annotation is part of a dosing algorithm table based on 8 genetic variants.,Allele A is associated with dose of warfarin as compared to allele del.,A,
1448109696,rs28371685,CYP2C9,warfarin,27121899,Dosage,not stated,This variant annotation is part of a dosing algorithm table based on 8 genetic variants.,Allele C is associated with dose of warfarin as compared to allele T.,C,
1449005218,rs2108622,CYP4F2,warfarin,28262345,Dosage,yes,,Genotypes CC + CT are associated with decreased dose of warfarin as compared to genotype TT.,CC + CT,
1449575733,rs2108622,CYP4F2,warfarin,29875668,Dosage,no,"There were no significant differences in mean warfarin stable dose (mg/week) (+3 INR stable, no dose change) in the overall group or in the identified ""white"" subgroup. The self-identified ""non-white"" subgroup had slight differences in mean warfarin doses (ANOVA p= 0.048 CC = 29.2, CT = 33.1, TT = 33.0). Two self-reported ""non-white"" patients had the TT genotype.",Allele T is not associated with dose of warfarin as compared to allele C.,T,
1449575721,rs1045642,ABCB1,warfarin,29875668,Dosage,no,"Univariate analysis only. Association was signficant in the overall group, and in the self-reported ""non-white"" patients, but not in the self-reported ""white"" patients.",Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.,GG,
1449165091,rs9923231,VKORC1,warfarin,28382498,Metabolism/PK,yes,Please note: alleles have been complemented to the + chromosomal strand.,Allele C is associated with increased dose of warfarin as compared to allele T.,C,
1449165085,rs9923231,VKORC1,warfarin,28382498,Metabolism/PK,yes,(S)-and (R)-W steady-state concentrations (mg/mL) for AA (0.54 (0.39–0.68) > AG (0.76 (0.60–0.92) >GG (1.05 (0.91–0.1.19)). Please note: alleles have been complemented to the + strand.,Allele C is associated with increased steady-state concentration of warfarin as compared to allele T.,C,
1449246784,rs1051740,EPHX1,warfarin,28049362,Dosage,no,,Allele C is not associated with dose of warfarin as compared to allele T.,C,
1449250615,rs11676382,GGCX,warfarin,28049362,Dosage,no,,Allele G is not associated with dose of warfarin as compared to allele C.,G,
1449262642,rs9923231,VKORC1,warfarin,29568565,Dosage,yes,,Allele T is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.,T,
1449164037,rs11168293,VDR,warfarin,29298995,Dosage,yes,"This SNP is in very tight linkage disequilibrium with rs11168292 and rs4760658 (r2>0.97). Mean dose (in mg) of warfarin according to genotype was: TT>GT>GG. p-value adjusted for CYP2C9 metabolizer status and VKORC1 activity status phenotypes, among other factors. Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation.",Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT.,TT,
1449164047,CYP2C9 normal metabolizers,CYP2C9,warfarin,29298995,Dosage,yes,Mean dose (in mg) of warfarin according to metabolizer phenotype was: EM>IM>PM. Metabolizer phenotype was based on presence of CYP2C9*2 and *3. Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation.,CYP2C9 normal metabolizers are associated with increased dose of warfarin as compared to CYP2C9 poor metabolizers and intermediate metabolizers.,,
1449164060,VKORC1 low activity,VKORC1,warfarin,29298995,Dosage,yes,"Mean dose (in mg) of warfarin according to activity phenotype was: High Activity (HA)>Intermediate Activity (IA)>Poor Activity (PA). Activity phenotype was based on presence of VKORC1*2, *3 and *4. Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation.",VKORC1 low activity is associated with decreased dose of warfarin.,,
1447520031,"CYP2C9*1, CYP2C9*2, CYP2C9*3",CYP2C9,warfarin,26469104,Dosage,yes,"CYP2C9*2 and/or *3 genotypes were characterized by lower estimated warfarin dose (median, 21 vs. 35 mg/week, p=0.02).",CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,*2 + *3,
1184757055,rs7542281,F5,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele C is not associated with dose of warfarin in people with heart valve replacement as compared to allele T.,C,
1448276167,rs7294,VKORC1,warfarin,21326313,Dosage,yes,"The mean warfarin dose was higher in patients with the TT genotype (5.0+/-0.8 mg/day) as compared to those with the CC genotype (3.0+/-1.5 mg.day). This variant was in linkage disequilibrium with rs9934438, rs2359612 and rs8050894. Please note that alleles have been complemented to the plus chromosomal strand.",Genotype TT is associated with increased dose of warfarin as compared to genotype CC.,TT,
769168963,rs12714145,GGCX,warfarin,20694283,Dosage,no,This variant was not a significant predictor of warfarin dose,Allele T is not associated with dose of warfarin as compared to allele C.,T,
1447680544,rs9923231,VKORC1,warfarin,26739746,Dosage,yes,,Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.,CT + TT,
1448257083,rs9923231,VKORC1,warfarin,27488389,Dosage,yes,in Han Chinese,Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.,TT,
1184512419,rs7856096,FPGS,warfarin,25079360,Dosage,yes,"In the discovery cohort the uncorrected p-value was 1.82E-8. P-values were adjusted using Bonferroni correction, with a significance cutoff of 3.22E-7 based on the 155,186 SNPs tested in the discovery cohort.",Allele G is associated with decreased dose of warfarin as compared to allele A.,G,
1183699320,rs1057910,CYP2C9,warfarin,17387222,Dosage,yes,C (*3) was associated with 38.1 %(95% CI 29.3 -45.7%) reduction in therapeutic dose (defined as the dose that gave an INR in the target therapeutic range after 7 consecutive days) per copy.,Allele C is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele A.,C,
982036698,rs1057910,CYP2C9,warfarin,18542936,Dosage,yes,"in Turkish patients taking warfarin for >2 months. This variant defines CYP2C9*3. Homozygous variant genotype (*2/*2,*2/*3,and *3/*3) are grouped together, and heterozygous variant genotype (*1/*2,*1/*3,and *1/*4) are grouped together for analysis. Patients carrying one or two copies of CYP2C9 variant alleles are associated with lower dose of warfarin as compared to the homozygous wild type patients.",Allele C is associated with decreased dose of warfarin as compared to allele A.,C,
1184757008,rs3093105,CYP4F2,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele C is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.,C,
1184757018,rs3093158,CYP4F2,warfarin,25126975,Dosage,no,"Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that ""SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model.""",Allele T is not associated with dose of warfarin in people with heart valve replacement as compared to allele C.,T,
